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Elucidation Of Cancer Therapy Resistance Mechanisms Due To Altered
Endoplasmic Reticulum-Mitochondria Tethering
Abstract
Many neuroblastoma patients die from progression of multidrug resistant disease, the etiology of which
remains poorly understood. Mitochondria (mito) integrate diverse stress and survival signals to determine
whether a cell lives or dies. Importantly, apoptotic sensitivity is modulated at mitochondria by interactions
with endoplasmic reticulum (ER) at specialized contact sites essential for calcium (Ca2+) and lipid
transfer between the organelles. ER-mitochondria contact sites (ERMCs) are enriched for protein
complexes, including MFN2 and PACS2, that bridge the organelles. Here, I define a novel mechanism for
chemotherapy resistance caused by reductions in ERMC tethers and provide functional validation for this
relationship. I studied neuroblastomas from diagnosis (DX, largely chemosensitive) and relapse (REL,
chemoresistant) obtained from the same patients. Functional mitochondrial profiling showed that REL
neuroblastoma mitochondria are markedly reduced in apoptotic responses to stress and this correlates
with chemoresistance across drug classes. These differences are highly reproducible and were not
caused by changes in mitochondria biomass or mtDNA content. Instead, REL cells show reduced ERMC
numbers and/or increased gap-distance compared with patient-matched DX cells. The impact of reduced
ERMC connectivity was confirmed using multiple orthogonal methods. MFN2 or PACS2 silencing in DX
cells attenuated mitochondrial responses, phenocopied resistance and reduced ERMC tethering. As a
consequence, ERMC Ca2+ transfer was decreased in REL cells. On the other hand, enhancing ERMC
connectivity using synthetic linkers restored Ca2+ transfer. ERMCs serve as physiologic regulators of
apoptosis, and I show in patient-matched tumor models that these contacts are markedly reduced in
therapy resistant cells. Some resistant cells had reduced numbers of ERMC tethers (and reduced Ca2+
transfer), while other resistant cells had preserved numbers of tethers (and preserved Ca2+ transfer), but
an abnormally increased gap distance. The outcomes of this work reveal the contributions of a “socially
distanced ER-mito phenotype” to cancer therapy resistance, a novel model for the development of clinical
tools to measure ERMC interactions, and the identification of therapeutic opportunities to revert
resistance.
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ABSTRACT
ELUCIDATING CANCER THERAPY RESISTANCE MECHANISMS DUE TO ALTERED
MITOCHONDRIA-ENDOPLASMIC RETICULUM CONTACT SITES
Jorida Coku
Michael D. Hogarty

Many neuroblastoma patients die from progression of multidrug resistant
disease, the etiology of which remains poorly understood. Mitochondria (mito) integrate
diverse stress and survival signals to determine whether a cell lives or dies. Importantly,
apoptotic sensitivity is modulated at mitochondria by interactions with endoplasmic
reticulum (ER) at specialized contact sites essential for calcium (Ca2+) and lipid transfer
between the organelles. ER-mitochondria contact sites (ERMCs) are enriched for protein
complexes, including MFN2 and PACS2, that bridge the organelles. Here, I define a
novel mechanism for chemotherapy resistance caused by reductions in ERMC tethers
and provide functional validation for this relationship.
I studied neuroblastomas from diagnosis (DX, largely chemosensitive) and
relapse

(REL,

chemoresistant)

obtained

from

the

same

patients.

Functional

mitochondrial profiling showed that REL neuroblastoma mitochondria are markedly
reduced in apoptotic responses to stress and this correlates with chemoresistance
across drug classes. These differences are highly reproducible and were not caused by
changes in mitochondria biomass or mtDNA content. Instead, REL cells show reduced
ERMC numbers and/or increased gap-distance compared with patient-matched DX
cells. The impact of reduced ERMC connectivity was confirmed using multiple
orthogonal methods. MFN2 or PACS2 silencing in DX cells attenuated mitochondrial
responses, phenocopied resistance and reduced ERMC tethering. Consequently, ERMC
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Ca2+ transfer was decreased in REL cells. On the other hand, enhancing ERMC
connectivity using synthetic linkers restored Ca2+ transfer.
ERMCs serve as physiologic regulators of apoptosis, and I show in patientmatched tumor models that these contacts are markedly reduced in therapy resistant
cells. Some resistant cells had reduced numbers of ERMC tethers (and reduced Ca2+
transfer), while other resistant cells had preserved numbers of tethers (and preserved
Ca2+ transfer), but an abnormally increased gap distance. The outcomes of this work
reveal the contributions of a “socially distanced ER-mito phenotype” to cancer therapy
resistance, a novel model for the development of clinical tools to measure ERMC
interactions, and the identification of therapeutic opportunities to revert resistance.
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CHAPTER 1: BACKGROUND
1.1 Genesis
As early as the 1950s, French microscopists captured the close association of
the endoplasmic reticulum membranes with mitochondria in rat liver electron
micrographs and fish gills1–3. However, the biological and physiological relevance of
ERMCs was overlooked because of their relative abundance and ubiquity across various
cell types.

The ER membranes that accompanied mitochondria after subcellular

fractionations of rat liver by standard centrifugation, were categorically disregarded as
ER

contaminants.

Not

until

the

early

1990s,

when

better

Percoll

gradient

ultracentrifugation techniques were developed, did these contact sites attract the
deserved attention and their role gain prominence. Seminal in this field was the work of
Dr. Jean Vance who demonstrated in her 1990 paper that ERMCs were crucibles for
lipid synthesis and portals for the transfer of lipids between the two organelles, revealing
the long-standing mystery of how mitochondria obtain certain lipids, which turned out to
be ferried from the ER4.
In the last 30 years since Vance’s discovery, thanks in part to advances in
imaging technology, irrefutable evidence has emerged of ERMCs importance in signal
transduction, bioenergetics, cell death, lipid metabolism, and pathophysiology of human
diseases. Dysfunction of ERMCs has been implicated in a plethora of neurodegenerative
diseases, including Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral
sclerosis5–14 as well as metabolic disorders such as diabetes15–21, suggesting that the
deregulation of this process may have broad relevance in disease.

1

Little did I know that my research work in Dr. Eric Schon’s lab would pave the
road to the discovery of ERMCs in cancer therapy resistance. Back in 2008, as part of
my master’s thesis research, I had investigated the communication between these two
organelles in the context of Alzheimer’s disease in which a gain of function (increased
apposition) resulted in neuronal cell death. I worked on assessing MAM integrity by
measuring the interaction of two lipid enzymes (SCD1 and DGAT2) in mouse embryonic
fibroblasts with knock-down of presenilin 1 and 2 (a protein located in the MAM and
mutated in Alzheimer’s).
In December 2014, I met with Dr. Michael Hogarty to discuss the possibility of
conducting my third rotation in his laboratory. When he started explaining all the
available research projects, I could not believe my ears and serendipity. Dr. Hogarty’s
research focus on pediatric cancer had sparked my curiosity because it intertwined my
interests and previous separate experience in mitochondrial diseases and cancer
research. However, I did not expect to hear that ERMCs were a subject of his interest
and investigation in cancer, potentially comprising a mechanism of therapy resistance in
neuroblastoma, a highly lethal pediatric tumor. After he had finished talking, I remember
saying instinctively “I want this project!”. Indeed, a decade later, my thesis work would
set me on the same mission, but on a different direction: defining how ERMC loss of
function or “increased social distancing” between these organelles would define a novel
contribution to cancer therapy resistance in neuroblastoma. Though the underlying
mechanisms of how ERMCs are regulated remain mysteries to be solved for this exciting
field, here we take the first strides to ascertain their implications and importance in the
progression of multidrug resistance in cancer.
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Street, Box 2140, Genentech Hall,
San Francisco, CA 94158, USA

across all cancers [47–49]. Such heterogeneity can promote ‘varied’ or ‘no’ response to
therapy [50–52].

Tumor heterogeneity evolves temporally over time with tumor progression or with changes in *Correspondence:
therapy and spatially from primary to metastatic tumors [53–55]. Tumor evolution, which trever.bivona@ucsf.edu (T.G. Bivona).
describes the emergence of multiple distinct subpopulations of cancer cells within the same
tumor or patient, is a key feature of cancer progression and relapse and plays a key role in drug
resistance [56]. Although cancers usually arise by clonal outgrowth from a single founder cell
1.2
Cancer Therapy Resistance Mechanisms
[57], the expansion of the daughter cells of the founder cell after malignant transformation
coupled with the continuous acquisition of alterations and/or mutations promote the emerthe global
of all maladies
cancer
claims 600,000
people every year
gence ofAs
divergent
canceremperor
cell subpopulations
and an increase
in heterogeneity
(as reviewed
elsewhere [58]; Figure 1). Alterations that occur early in tumor evolution are clonal, whereas
inthose
theacquired
US alone.
patients
die leads
fromto the
cancer
have
progression of therapy
later are Most
subclonal
[54], Drugwho
treatment
elimination
of drug-sensitive
subpopulations, tumor microenvironment alteration, and positive selection of a drug-resistant
resistant
tumors.
Emergent
resistance
to diverse
treatments
(chemotherapy,
radiation
subpopulation
of cells,
which can result
in a decrease
in heterogeneity
at least
temporarily
[56,58] (Figure 1). Expansion of the resistant subpopulation rapidly re-establishes heterogeneity
through the
acquisition
of new mutations
that distinct
provide survival
beneﬁts to the
of
therapy
and
immunotherapy)
with
mechanisms
of daughter
activity,cells
termed
multidrug
the resistant subclone [58] (Figure 1).

resistance (MDR), is the principal cause of cancer treatment failure and death. MDR
Tumor heterogeneity arises due to both genetic and epigenetic changes in tumor cells and in
cells
thebarrier
tumor microenvironment
[54,59]. treatment,
Genetic changes
chromosomalcauses remain
posescomprising
a critical
to effective cancer
yetdue
its tounderlying
instability or genome duplication events as well as a variety of transcriptional states generated
by epigenetic changes through altered DNA methylation and histone modiﬁcations contribute
obscure22.
to tumor heterogeneity [54,59,60]. The presence of different lineage-speciﬁc gene expression
programs within tumor cell subpopulations can also contribute to tumor heterogeneity [11].
Differences
in the tumor
microenvironment,
such
the tumor-resident
In clinical
practice,
MDR refers
to asa heterogeneity
progressiveindisease
that occurs at doses
stromal cells from one tissue type to another (e.g., lung versus liver), are another form of tumor
heterogeneitywith
that can
also contribute
to residual
drug resistance
associated
manageable
toxicity.
In disease
cancerand
treatment,
the [34,42,61].
therapeutic index is a

measure
of Mechanisms
the clinical
Figure
1. Different
of
Drug Resistance in Cancer. Drug

Drug resistance

Mul!factorial,
co-occurence

Gene!c

Nongene!c

Heterogeneity,
tumor evolu!on

Other

Temporal

Spa!al

Figure 1.2.1: Different mechanisms of drug
resistance in cancer. Drug resistance is
multifactorial and heterogenous. The underlying
mechanisms of drug resistance are diverse and
complex, and often not mutually exclusive. Drug
resistance is driven by both genetic and epigenetic
mechanisms as well as by several other factors,
including drug transporters and adaptive signaling
events in tumor cells as well as tumor
microenvironment features
(Chatterjee and Bivona, 2019).

benefit of

resistance is multifactorial and heterogetreatment relative to its toxicity. Since
nous and poses serious challenges to
cancer treatment. The underlying
mechanisms
drug resistance are
most ofchemotherapeutic
agents
diverse and complex, and often not
mutually exclusive. Drug resistance is dripossess
a low and
therapeutic
index, even
ven
by both genetic
epigenetic
mechanisms as well as by several other
factors, including drug transporters and
small-fold changes in the sensitivity of
adaptive signaling events in tumor cells,
as well as tumor microenvironment
features.
tumor cells can render them clinically

resistant, and the patient
presenting
Trends in Cancer, March 2019, Vol. 5, No. 3
with MDR23.MDR can is a complex
phenomenon, multifactorial in nature
and

characterized

heterogeneity,

which

by

tumor
evolves

temporally during the course of therapy and spatially as the primary tumor becomes
metastatic. Additionally, both genetic and nongenetic mechanisms, such as lineage
plasticity/switching (a change in cell identity) or epigenetic factors that promote gene
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expression changes and phenotypic plasticity are recognized in driving cancer drug
resistance in a non-mutually exclusive manner (Figure 1.2.1)24. A myriad of ways in
which cancer cells can become recalcitrant to therapy exist. Clinical failure of
chemotherapy fall into three broad categories:

pharmacokinetic, tumor micro-

environmental and cancer-cell specific (Figure 1.2.2)23. The resistance mechanism
elucidated here however, pertains to the last category.
REVIEWS
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1.2.2:
Drug-resistance
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failure
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chemotherapy
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drug
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can beinclude
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FIRST-PASS METABOpharmacokinetics,
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apoptotic signaling or the
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apoptotic
radioresistance,effector
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Text
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promoting
death;
green,generation of free radicals, enhanced drug detoxification,
pathways
mediating
drug
increased genomic instability, and/or HIF1 (hypoxiaresistance;
brown,
pathways
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chemosensitivity — cells grown as monolayers often
show different sensitivities to cytotoxic agents when
compared with the same cells grown as spheroids in suspension32,33. This might also be mediated by cell-cycle
proteins such as KIP1 (REF. 34). Cell-surface signalling,
which
mediated by integrins
and cadherins,
the PHOSAt the cellular level, MDR to anti-cancer agents can
beis classified
into two
general
PHATIDYLINOSITOL 3-KINASE (PI3K) PATHWAY, and pro-apoptotic
proteins such as BIM and BMF, have also been impliclasses: intrinsic resistance and acquired (adaptive) resistance.
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ence drug–target interactions and subsequent cell dammutant p53 cell lines to paclitaxel26.
age. In addition, it has traditionally been hypothesized
employed by cancer
cells to evade apoptosis. Both forms
of resistance are thought to
that drug resistance develops as a result of progressively
Drug resistance
acquired somatic mutations or epigenetic changes
Drug resistance is thought to cause treatment failure and
PROGRESSIVE DISEASE
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over time35. However,
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it is important to consider that cytotoxic agents are pridisease. In clinical practice, drug resistance refers to PROsum of the maximum diameter
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-4- with man- marily effective against proliferating cells and that, even
GRESSIVE DISEASE that occurs at doses associated
appearance of one or more new
ageable toxicity. As most chemotherapeutic agents have a
in rapidly proliferating tumours, a significant proporlesions.
low THERAPEUTIC INDEX, even small-fold changes in the sention of cancer cells are in a quiescent state. These quiessitivity of tumour cells in patients can render them clinicent cells therefore show a degree of drug resistance
THERAPEUTIC INDEX
Measures the clinical benefit of a
cally resistant. Reasons for the clinical failure of
relative to cycling cells36. So, it seems likely that two partreatment relative to its toxicity.
chemotherapy and ‘apparent drug resistance’ can be clasallel phenomena underlie clinical drug resistance in
sified into three broad categories: PHARMACOKINETIC,
ovarian cancer, and this is illustrated in FIG. 2.
PHARMACOKINETICS
tumour micro-environmental and cancer-cell specific. A
Alterations in drug influx and efflux due to cell-memProcesses that are involved in the
brane transport proteins such as P-glycoprotein (PGP),
general model of the interactions between these varied
distribution and metabolism of
a drug in an organism.
multidrug-resistance protein (MRP) and lung-resistance
mechanisms is illustrated in FIG. 1.
Figure 1 | Drug-resistance mechanisms. Mechanisms of failure of chemotherapy and drug
resistance can be due to pharmacokinetics, the tumour micro-environment or cancer-cell-specific
issues. These influence the response to chemotherapy by principally affecting intracellular active
drug concentrations, drug–target interactions, target-mediated cell damage, damage-induced
apoptotic signalling or the apoptotic effector machinery. Text boxes: yellow, pathway of drug action;
blue, pathways promoting cell death; green, pathways mediating drug resistance; brown, pathways
with potentially both pro- and anti-cytotoxic effects. TS, tumour suppressor; EC, extracellular.

cancer cells with the ability to self-renew and to differentiate into the heterogeneous
lineages of cancer cells in response to chemotherapy25.

Figure 1.2.3: Cancer stem cells survive anti-cancer drug treatment. Mutations (point
mutations, gene amplifications etc.) in these cancer stem cells (CSC) lead to anti-cancer drug
resistant phenotypes. Cancer stem cells that survive anti-cancer drug treatment proliferate and
lead to anti-cancer drug resistance (intrinsic resistance) (Phi et al., 2018).

Though successful cancer therapy abolishes the bulk of proliferating tumor cells,
the subset of remaining CSCs that survive can promote cancer chemoresistance and
relapse due to their ability to establish higher invasiveness and chemoresistance.
Neuroblastoma is a neuroendocrine childhood tumor that originates from pluripotent
progenitor cells that confer a high level of tumor heterogeneity to it. Such tumor initiating
cells have been associated with neuroblastoma epigenetic dysregulation and a failure to
26

implement a differentiation program . However, since CSSs are known to develop
FIGURE
1 | The mechanisms of anti-cancer drug resistance. (A) Drug efflux by ABC transporte
anti-cancer
drug
resistance.
DNA damageagents,
repair their
alsocontribution
leads to anti-cancer
resistance
to treatment
withIncreased
single chemotherapeutic
does not drug resist
Mutations (point mutations, gene amplifications etc.) in these cancer stem
cells lead to anti-canc
explain broad acquired therapy resistance resulting after multimodal therapy27.
anti-cancer drug treatment proliferates and lead to anti0cancer drug resistance (intrinsic resistan
cells are selected on treatment by reversible epigenetic reprogramming. Further epigenetic repro
mutation in slow-cycling drug-tolerant cells also give rise to permanent drug-resistant cells. HAT
closely related to increased drug resistance and invasiveness. MET denotes mesenchymal-epith
resistance. BRAF inhibitor resistance develops from gene amplification, gene overexpression, ge
of HDACs.
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(Ahn et al., 2017). Figure 1 shows the mechanisms of anti-cancer
drugs resistance. Tumor heterogeneity and plasticity (phenotypic
switching) are responsible for resistance to various anti-cancer

BRAFV60
AKT1(Q7
inhibitor

Traditionally, the biochemical
underpinnings
include:

of

acquired

alterations

to

MDR
drug

metabolism, increased drug efflux,
decreased drug uptake, modification
of the drug targets, amplification of
targeted

protein,

genetic

rewiring,

enhanced DNA repair, inactivation of
apoptotic proteins, or activation of
anti-apoptotic ones, among others

Figure 1.2.4. The mechanisms of drug
resistance in the cancer cells. Cancer cells will
become resistant to drugs by the mechanisms
such as the inactivation of the drug, multi-drug
resistance, cell death inhibition (apoptosis
suppression), altering in the drug metabolism,
epigenetic changing, changes in the drug targets,
enhances
DNA-repair
and
target
gene
amplification. (Mansoori et al., 2017)

(Figure 1.2.4)28–30. A different way of classifying of acquired cancer-cell specific MDR
mechanisms would be to group them in the drug-effector cascade as “pre-target”,
occurring prior to the drug reaching its target, “on target” leading to modification of the
drug substrate and “post-target”, occurring downstream of a target at a focal point where
all cytotoxic stress signals are integrated (Figure 1.2.5).
Drug efflux via ABC transporters like P-glycoprotein protein have been implicated
in therapy resistance31,32. However, many multidrug resistant tumors are devoid of such
alterations, many cancer drugs for which resistance emerges are not substrates of efflux
transporters, and efforts to block efflux have not met with success in the clinic. Recent
focus has shifted to selective resistance to molecularly targeted agents, such as
gatekeeper mutations encoding resistance to inhibitors of activated kinases33,34. While
such “on-target” mutations or activation of bypass signaling do contribute to resistance in
these settings, they do not account for most of the resistance to targeted agents or to the
profound multidrug resistance encountered in the clinic. Blockade of apoptotic signaling
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at more distal nodes (“post-target”) provides a more effective resistance strategy, as it
provides resistance to diverse cellular stressors.
Considering that many tumors have a paucity of mutations or epigenetic
modifications underlying their resistance and, that resistance effectors are not randomly
distributed, we reasoned that the tumor’s addiction to survival bias would most likely be
non-genetic and occur at a post-target location where all the therapeutic stressors
converge to execute cell death: the mitochondria35. The more capable of modifying their
mitochondria to resist death signals, the more invincible the tumors would be. Though
not exclusive of any of other resistance mechanisms, this cancer survival bias would be
agnostic of any genetic drivers, of any inherent tumor heterogeneity or epigenetic
factors, and capable of conferring superior adaptation to increased therapeutic stress
and clinically manifesting as broad therapy resistance or pan-resistance.
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Pre-target

Drug X

Increased drug efflux (Pgp/MDR1)
Decreased drug uptake
Alterations of drug metabolism
(increased CyP450 expression)
Enhanced detoxification
Drug sequestration/compartmentalization

§
§
§

Drug X

§
§

Drug Target

Mcl1
Bcl2

On-target
§
§
§

Tumor

Bypass signaling
Target mutation
Target amplification

Post-target
§
§
§
§

TP53 mutation
Enhanced DNA repair
Inactivation of apoptotic proteins
Activation of anti-apoptotic proteins

APOPTOSIS
Figure 1.2.5: A new classification of multidrug resistance mechanisms. Any stress on cancer
cells (therapeutic, genotoxic, metabolic, deprivational) can lead to survival adaptations that precede
the drug target such as: increased drug efflux by MDR-1 related proteins, decreased drug uptake,
drug metabolism alterations, enhanced detoxification and drug sequestration or
compartmentalization. On-target modifications directly affect the drug effector such as target
mutations that render it resistant to the effects of the drug, compensatory cellular target
amplifications, and bypass signaling such as activation of alternative RTKs that maintain the
signaling of key downstream pathways despite sustained inhibition of the original drug target. Posttarget mechanisms impinge directly on apoptotic pathways by dialing down mitochondrial apoptosis
sensitivity through inactivation of pro-apoptotic Bcl2-family members or inactivation of apoptotic
proteins and multiple alterations such as enhanced DNA repair or TP53 mutations that result in
defects in proapoptotic pathways and/or the aberrant activation of antiapoptotic pathways.
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1.3 Mitochondrial Pathway of Intrinsic Apoptosis
Mitochondria are both the engines for life, generating vital energy for cells to
carry their biological functions, as well as machineries for cell death36–38. Intrinsic and
extrinsic (therapeutic), stressors are integrated at this organelle to orchestrate apoptosis
Cameron
Fraser
al.
in a62
process
governed
byetB-cell
lymphoma 2 (Bcl2)-family proteins39,40.

Fig. 1 The mitochondrial apoptosis pathway. In this simplified schematic, cellular stress or damage signals
Figure 1.3.1: The mitochondrial apoptosis pathway. In this simplified schematic, cellular
(1) unleash proapoptotic proteins (BH3-only “activators” of apoptosis) (2), which can either be bound and
stress or damage signals (1) unleash proapoptotic proteins (BH3-only “activators” of apoptosis)
sequestered by prosurvival proteins such as BCL-2, BCL-XL or MCL-1 (3) or activate BAX and/or BAK (4).
(2), which can either be bound and sequestered by prosurvival proteins such as BCL-2, BCL-XL
Activation of BAX or BAK causes mitochondrial outer membrane permeabilization (MOMP), resulting in the
or MCL-1
(3) or activate BAX and/or BAK (4). Activation of BAX or BAK causes mitochondrial
release
of cytochrome
c from mitochondria
and consequent
caspases
for dismantling
outer
membrane
permeabilization
(MOMP),
resultingactivation
in the of
release
of (5)cytochrome
c of
from
the
cell
mitochondria and consequent activation of caspases (5) for dismantling of the cell (Fraser et al.,
2019).
have undergone this process, the cell is committed to apoptotic cell
This family includes diverse
that has
actbeen
as stress
signaling
death.BH3-only
The BH3 proteins
profiling assay
designedsentinels
to measure
the
amount and type of proapoptotic signal that is required for a given
through the obligate mitochondrial
executioners,
Bak or Bax, to induce mitochondrial
cell to trigger
apoptotic cell death.

outer
permeabilization
(MOMP),
the release
of understanding
apoptogenic factors
such as
Based on our
established
molecular
of apoptosis
1.2membrane
Mitochondrial
Apoptotic Priming

signaling and a multitude of experimental models, it is clear that

the stateAlternatively,
of this pathwayBH3-only
in a cell before
it is damaged
stressed can by
cytochrome C, and cell death.
proteins
can beorsequestered
impact cell fate. To illustrate, a living cell that expresses only
enoughtoprosurvival
proteins toactivation.
barely buffer
endogenousBcl-2
proapoppro-survival Bcl2 homologues
prevent Bak/Bax
Pro-survival
protein
totic signals is considered “primed” for apoptosis (Fig. 2). In
contrast,
cell that expresses
a surplus
of prosurvival
proteins
thatBH3
members also can sequester
BH3a activators
including
Bid, and
Bim (Figure
1.3.1).
can buffer against existing and potentially additional proapoptotic
41,42
is “unprimed.”
Finally,
cells
that do
notinteraction,
express sufficient
sensitizers such as BH3 molecules
mimetic molecule
ABT-737
disrupt
this
and the
levels of BAX and BAK to undergo MOMP and thus commit to
apoptosis
“apoptosis
Cells MOMP
that are and
primed
more
released activators directly
activateare
Bax
and Bakrefractory.”
to engendering
apoptosis.
readily undergo apoptosis in response to damage or stress than
unprimed cells and apoptosis refractory cells are completely pro-9- signaling and unable to die via this pathtected from proapoptotic
way [5]. Because the state of the apoptosis pathway can potentially
drive cell fate decisions in response to damage or stress, the BH3
profiling assay was developed, which measures apoptotic priming
within a given cell.
The BH3 profiling assay is based on measuring the extent of
MOMP that occurs in response to proapoptotic BH3 peptides
(Fig. 3), which mimic the activity of full-length proapoptotic

1.4 Mitochondrial Priming
Mitochondrial apoptotic priming, or the proximity of a cancer cell to its apoptotic
threshold, is a key determinant of treatment response38,43. Since mitochondria provide
platforms for integrating stress signals to determine cell survival or death and comprise a
node that broadly regulates chemosensitivity, capturing information on how the
mitochondria of resistant cancers differ from their sensitive counterparts becomes of
paramount importance when striving for better treatment response44–46.
To determine the propensity of bulk cancer cells to undergo apoptosis, the BH3
profiling assay can be employed. This assay involves the exposure of cellular
mitochondria, to proapoptotic BH3 death-domain peptides that bind all antiapoptotic
proteins with high affinity and also engage Bak and Bax to induce death. By probing
mitochondria with BH3 peptides that mimic the activity of endogenous proapoptotic
CA01CH15-Letai
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Figure 4 1.4.1: Apoptotic priming and cellular response to chemotherapy. Apoptosis can be
Figure
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response
to chemotherapy.
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considered
to occur
once
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such as going over the edge of a cliff. One can imagine that some cells are closer than others to the edge of the cliff. BH3 profiling with
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provide
a
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of
a
cell
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promiscuous BH3 peptides (Figure 2b) can provide a measure of the proximity to the cliff ’s edge. (a) Cells whose mitochondria are
edge.
(a)
Cells
whose
mitochondria
are relatively
sensitive
primed
for
relatively
sensitive
to BH3
peptides
are primed for apoptosis,
and close to the
edge. Whento
theyBH3
receivepeptides
proapoptotic are
signaling
as a
result of chemotherapy,
they aretoforced
commit toWhen
cell death.
(b) Cells
whose mitochondria
are relatively
insensitiveas
to BH3
peptides of
apoptosis,
and close
theto edge.
they
receive
proapoptotic
signaling
a result
are unprimed for apoptosis
and farther
from
cliff ’s edge.
they receive
signalmitochondria
from chemotherapy,
they
move
chemotherapy,
they are
forced
tothecommit
toWhen
cell death.
(b)a proapoptotic
Cells whose
are
relatively
closer to the edge, but are not compelled to commit to apoptosis. (c) With a series of proapoptotic pulses from different agents,
insensitive
unprimed
for apoptosis
andkeyfarther
the
cliff agents
’s edge.
unprimed cellsto
canBH3
first bepeptides
primed, and are
then compelled
to commit
to cell death. The
will be tofrom
identify
targeted
that When
they
receive
proapoptotic
signal
from
they cells.
move closer to the edge, but are not
selectively
induceacancer
cell proapoptotic
signaling
withchemotherapy,
minimal toxicity to normal
compelled to commit to apoptosis. (c) With a series of proapoptotic pulses from different agents,
unprimed
cells can first be primed, and then compelled to commit to cell death. (Letai, 2016).
However, some cells perch close to the threshold of commitment to apoptosis, whereas others

-10perch further away (Figure 4). The former cells commit to
apoptosis, whereas the latter survive.
To test this hypothesis, one would need a tool that can measure the proximity of a cell to the
apoptotic threshold. We have used BH3 profiling with so-called promiscuous BH3 peptides
(see Figure 2b), peptides that bind all antiapoptotic proteins with high affinity. Mitochondrial
sensitivity to such peptides gives a measure of overall antiapoptotic reserve, and hence proximity
to the threshold. We refer to cells or mitochondria that are more sensitive to these peptides as
being more primed. We have now conducted clinical experiments in AML, ALL, CLL, multiple
myeloma, and ovarian cancer. In each case, the pretreatment apoptotic priming of patient cancer

determined47. Mitochondrial sensitivity to such peptides provides a measure of overall
anti-apoptotic reserve, functionality of Bak and Bax, and consequently the proximity to
the death threshold (Figure 1.4.1)36.

1.5 Endoplasmic Reticulum and Mitochondria Contact Sites
Mitochondrial

activities

are

intimately linked to the functions of
endoplasmic reticulum (ER), a major
Ca2+

storing

organelle

in

close

proximity to mitochondria. Both are
tubular

organelles

characteristic
that

facilitates

with

“network
the

a

structure”

formation

of

interorganellar connections at ERmitochondria contact sites (ERMCs),
essential

for

the

transfer

of

calcium48–52 and lipid signals53–57 and

Figure 1.5.1: MAMs serve as microdomains
(highlighted in box) to provide essential factors
that support Bcl2 signaling and the activation of
MOMP (red) downstream of stress stimuli (blue).
Central hypothesis. Reduced tethering selected for
under therapeutic stress attenuates apoptotic
signaling leading to therapy resistance. How
mitochondrial fusion/fission, chronic ER stress and
ERAD signals regulate ER-mitochondria tethering
are
lacking.
MAM,
mitochondria-associated
membranes; MOMP, mitochondria outer membrane
permeabilization.

regulation of apoptotic sensitivity58–63 (Figure 1.5.1). ERMCs are fluid dancers that come
together without physically touching.

Though they are stabilized by multiple

proteinaceous tethering/functional complexes, the respective membranes maintain their
own identity, and do not undergo membrane fusion. Fusion normally occurs when lipid
bilayers are forced into a proximity of 1–2 nm. However, when in close apposition, fusion
is inhibited by either repulsion, which increases exponentially as the water molecules
that hydrate the phospholipid heads are squeezed out, or by spacing which is mediated
by the tethering proteins resident at the contact sites. A minimum of 10–30 nm spacing
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is required to accommodate the various protein bridges linking the mitochondria
associated membranes (MAMs) of the ER to mitochondria, especially the IP3R-GRP75VDAC1 calcium transfer conduit that extends ~ 25 nm (Figure 1.6.1). Hence, all
reported contacts are not closer than 10 nm in distance64.
Proteomic screens of MAM isolated from mammalian cells and tissues has led to
identification of multiple tethering complexes operating at ERMC as described below65,66:
(MFN2): Mitofusin 2 (MFN2) localizes not only to the mitochondria but also to the
ER and MAMs, forming both homo and heterotypic interactions with mitochondrial MFN2
and MFN116,67,68. MFN2 activity at the ERMC is regulated by a mitochondrial ubiquitin
ligase called MITOL. MITOL regulates MAM formation by enhancing MFN2 activity, as
illustrated by the reduction in ER Ca2 + transfer that occurs in MITOL-deficient cells69.
IP3R-GRP75-VDAC1: ER transmembrane protein inositol 1,4,5-trisphosphate
receptor (IP3R)70–73 is the main conduit responsible for Ca2 + release from the ER to the
mitochondria via the voltage dependent anion channel (VDAC1)74–77 at the outer
mitochondrial membrane (OMM), mediated by the molecular chaperone glucoseregulated protein 75 (GRP75)18,78,79. Knock-down of GRP75 abolishes the functional
IP3R-GRP75-VDAC1 MAM-mitochondria coupling, diminishing the normal Ca2+ transfer
to the mitochondria and reduces cell death in brain-derived tumor cells with tightly
coupled ERMC, rendering them resistant to oxidative cell death80. The anti-apoptotic
factor Bcl-2 has been shown to interact with IP3R to limit Ca2+ filling of the ER, leading to
reduced efflux at ERMC and preventing collapse of the mitochondrial membrane
potential (mtΔΨ) post-apoptotic stimuli81.
FIS-BAP31: The B-cell-receptor-associated protein 31 (BAP31) is an ER integral
membrane protein cleaved by caspases during apoptosis. The cytosolic region of the ER
Bap31 is cleaved by activated caspase-8 to generate proapoptotic p20Bap31, which
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causes rapid transmission of ER Ca2+ signals to mitochondria via the IP3R82,83. BAP31
interacts physically and constitutively with FIS1, a mitochondrial outer membrane protein
important for recruiting dynamin related protein 1 (DRP1) to mitochondria during
mitochondrial fission. Caspase cleavage of BAP31 activates DRP1-dependent fission of
mitochondria84.
PACS2:

Phosphofurin

acidic

cluster

sorting

protein

2

(PACS2)

is

a

multifunctional ER sorting protein that controls ERMCs and ER homeostasis85–87,17. In
addition, in response to apoptotic inducers, PACS2 translocates Bid to mitochondria,
initiating a sequence of events that include the formation of mitochondrial truncated Bid
(t-Bid) and the release of cytochrome c. Furthermore, PACS2 interacts with calnexin, a
Ca2 +-binding and quality control chaperon that resides at MAMs. Depletion of PACS-2
leads to calnexin removal and BAP31-dependent mitochondria fragmentation and
uncoupling from the ER88,89.
VAPB-PTPIP51: The ER vesicle-associated membrane protein-associated
protein (VAPB) binds to the outer mitochondrial membrane protein, protein tyrosine
phosphatase interacting protein 51 (PTPIP51) to tether the ER with mitochondria.
Disruption of VAPB-PTPIP51 interaction is pathogenic in both temporal cortex pyramidal
neurons in early Alzheimer's disease and amyotrophic lateral sclerosis and
frontotemporal dementia (ALS/FTD)11,90–93.
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1.6 Calcium Signaling at Endoplasmic Reticulum and
Mitochondria Contact Sites
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Figure 1.6.1: ER-mitochondria Ca2+ schematic.
At close MAM-mitochondria microdomain (10-30
nm) Ca2+ transfer occurs through the IP3RGRP75-VDAC axis. Mitochondria takes up
calcium into the matrix via MCU. Ca2+ overload
causes MOMP, mitochondrial fission, cristae
remodeling, and cytochrome c release and
apoptosis.

with mitochondria is dynamically changed by an elevation of the cytosolic Ca2+
concentration at the MAM. ER-derived Ca2+ release arrests the movements of
neighboring mitochondria, thus easing their close opposition to the ER membrane, which
favors mitochondrial Ca2+ buffering50,52.
The distance between the two juxtaposed membranes in turn, regulates the
extent of Ca2+ flux which cannot transverse the gap distance if the two membranes are
more than 100 nm apart. It is important to note that the physical architecture of ERMCs
can limit the assembly of this particular Ca2+ transfer machinery and impair the process
in return50. About 5–20% of the mitochondrial surfaces are closely apposed (10–30 nm
distance) to ER membranes94,95,59,96. Such close connections are required to properly
facilitate Ca2+ exchange between the two organelles (Figure 1.6.1). Decreasing the
distance of apposition between ER and mitochondrial membranes by synthetic linkers
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leads to mitochondrial Ca2+ overload95, whereas increasing the distance impairs
mitochondrial function resulting in cell death. Hence, monitoring Ca2+ exchange is a
physiological readout of ERMC associations.
Other players that can affect Ca2+ concentrations at the microdomains include
the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), a MAM enrich protein that
transports Ca2+ ions from the cytoplasm into the ER. SERCA overexpression increases
spontaneous and induced apoptosis via ER (Ca2+) overload97 whereas, alterations in ER
fatty acid and lipid composition result in the inhibition of SERCA activity and ER
stress98. Sigma-1 receptor (Sig1R), another MAM localized protein, forms a Ca2+
sensitive chaperone complex with GRP78 and prolongs Ca2+ signaling from the ER to
mitochondria by stabilizing type 3 IP3R99,100. Furthermore, the efficacy of ER derived
mitochondrial Ca2+ transfer depends not only on the ERMC distance, but also on
mitochondrial Ca2+ uptake via the mitochondrial Ca2+ uniporter (MCU), a transmembrane
protein on the IMM responsible for Ca2+ entry into the mitochondrial matrix (Figure
1.9)52,101–104.
Interestingly Ca2+ flux via the IP3R-GRP75-VDAC1 conduit12,71,105,106 has been
reported to be important determinant of treatment response and cancer cell death given
the fact that different chemotherapeutics (cisplatin, doxorubicin, ABT-737) rely on a
ERMC Ca2+ signaling component63,107,108. ABT-737 has been proposed to modulate the
sensitivity of cancer cells to chemotherapy via a mechanism that involves ERMC
remodeling109. Cisplatin resistant ovarian cells could be re-sensitized to cisplatin by ABT737 as evidenced by increased ERMCs and cisplatin-induced elevation in mitochondrial
Ca2+ 110. Hence, attenuated MOMP via ERMC uncoupling and decreased Ca2+ signaling
could be an adaptive survival response of cancer cells under intense and prolonged
therapeutic stress60,111.
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pathway [44,45], and in mitochondria by the decarboxylation of phosphatidylserine (PS) [46–48] (Fig. 1). In yeast, PE in mitochondria can
also be made from exogenously-supplied lyso-PE by the acyltransferase,
Ale1, that resides in the MAM [49,50]. The PS decarboxylation pathway
provides the majority of PE in at least some cell types [51]. For PE production by this pathway, PS must be imported from its site of synthesis in the
ER/MAM [15] to mitochondrial inner membranes where PS decarboxylase (PSD) is located [48,52] (Fig. 1). Thus, two distinct pools of PE can
Additionally, emerging evidence identifies
tumor
suppressors
potentially beseveral
generated:oncogenes,
one in the ER, the
other in
mitochondria. In
support of the idea that PE is compartmentalized on the basis of its
114
119
biosynthetic
the115–117
majority
PE in mitochondria
CHO
cells
and transcription factors including p53112113
, PTENorigin,
, Akt
, of
BRACA1
, PMLof120
and
[12] and yeast [53] is synthesized in mitochondria via PSD, rather than
in the ER from the CDP–ethanolamine pathway. In mammalian cells,
STAT3121,122 use the endoplasmic reticulum
a platform
control mitochondrial
the PE thatas
is synthesized
by PSDto
in mitochondria
is essential for the
normal functioning of mitochondria and cell survival. Elimination of
PSD in mice caused embryonic lethality and markedly altered mitochonapoptosis via ERMC Ca2+ and lipid signaling.
drial morphology [54]. Even a modest (25–30%) reduction in the PE
content of mitochondria in CHO cells profoundly altered mitochondrial
morphology and reduced cell growth, oxygen consumption and ATP
production via the mitochondrial electron transport chain [55].

1.7 Lipid Signaling at Endoplasmic Reticulum and Mitochondria
Contact Sites
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from the CDP–choline pathway. All mitochondrial PC is imported from the ER/MAM but
the mechanisms are unclear. Pathways that are presumed to occur are indicated by dotted
arrows. Pathways for which the mechanisms are not known are indicated by ?.

lipids like phosphatidylserine and ceramide53,124–127. An array of enzymes involved in the
final stages of lipid biosynthesis are integral MAM membrane proteins that co-isolate
with mitochondria (crude mitochondria), but can be separated from the latter by
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centrifugation of crude mitochondria on a Percoll gradient to yield purified MAM fraction
and pure mitochondria (Figure 1.7.2 A)4.
However,

mitochondria

also

contribute

to

the

cellular

synthesis

of

phosphatidylethanolamine (PE), which is an integral component of its inner membrane
and is synthesized from its ER derived precursor phosphatidylserine (PS), released from
mitochondria back to the ER (Figure 1.7.1 and 1.7.2B)128. Voelker proved the direct PS
transfer between the ER and mitochondria by demonstrating that the translocation and
the subsequent decarboxylation of PS can be attained by adding microsomes (from
donor MAM membranes) to purified mitochondria129,130.
In mammalian cells, PS is decarboxylated to PE by PS decarboxylase (PSD) in
IMM. PSD is essential for the normal mitochondria function and cell survival. PS
transport from the ER to mitochondria can be easily monitored following its conversion to
PE in mitochondria either within whole cells or in crude mitochondrial preps. The
synthesis of PS by phosphatidylserine synthase 1/2 (PSS1/2) in the MAM is indicative of
MAM functionality, whereas the conversion of PS into PE by PSD reflects the degree of
communication between the ER and mitochondria. The conversion of PS into PE
garners information about both, the MAM function (the “ER-side”) and ER-mitochondrial
communication (the “mitochondrial-side”)56.
Mitochondrial membranes also contain low amounts of sphingolipids that are
synthesized in the ER by sphingolipid breakdown by ceramide synthases131.
Mitochondrial ceramides form large stable barrel-like channels either alone or with Bax,
through which cytochrome c is released into the cytoplasm resulting in activation of
caspases and execution of apoptosis125,132. Ceramide is known as a “tumor suppressor
lipid” because of its p53 induced accumulation upon genotoxic stress133. The impairment
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of sphingolipid metabolism to reduce pro-apoptotic ceramide accumulation and its
contribution to cancer therapy resistance is well known132,134.
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(PA) that is transported from the endoplasmic reticulum (ER) to the IMM followed by a
the ER to mitochondrial outer membranes. Later studies can transfer lipids between membranes in vitro, did not
lipid composition of cells
showed that these ER-mitochondria contact sites are significantly alter membrane 135–138
cascade of enzymatic reactions at the matrix side of the IM (Figure 1.7.3)
. Hence,
abundant in cells and that 5 to 20% of mitochondria lie or tissues. In addition, vesicle transport of proteins with
associated
is to
notthe
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be aofmajor delivin close proximity
to the ER [23].
the accumulation
of CL is contingent upon PAtheir
transfer
from lipids
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ery process to mitochondria [reviewed in [31]]. We,
therefore,
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hypothesis
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physical juxtaRole of membrane
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the IMM. Furthermore, redistribution of CL depends
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The isolation of MAM led to the tantalizing idea that a position between mitochondrial outer membranes and
139,140
the
ER. (MAM) mediates the import of lipid molecules
close juxtaposition
of that
elements
of the negatively
ER with mitochonand IMM
aggregate
charged CL
dria might be required for specific biological functions, from the ER into mitochondria.
such as the inter-organelle (i.e. ER to mitochondria)-18- Phosphatidylethanolamine (PE) is a highly abundant
transport of lipids. The majority of membrane lipid syn- mitochondrial phospholipid that is essential for normal
thesis occurs on ER membranes whereas mitochondria mitochondrial functions [32, 33]. The majority of PE in
per se have only a limited capacity for lipid synthesis eukaryotic cells is produced by two distinct biosynthetic
and must, therefore, import most of their lipids from the pathways (Fig. 1b): (i) the CDP-ethanolamine pathway,
ER. Notable exceptions are a specific pool of phosphati- the final step of which occurs on ER membranes
dylserine (PS)-derived phosphatidylethanolamine (PE), [reviewed in [34]], and (ii) a pathway by which phospha-

CL plays an essential role in apoptosis and is most known for anchoring retaining
cytochrome c at the IMM. CL directly interacts with cytochrome c and affects its release
from the IMS into the cytosol141. The membrane-bound state of cytochrome c is
regulated by both CL levels as well as by CL’s oxidative state142. Oxidation, depletion or
impairment remodeling of CL stimulates the release of cytochrome c from the
membrane-bound state. Upon apoptosis induction, CL binds with members of the
apoptotic machinery such as t-Bid in at the mitochondrial contact sites and provides a
platform for the oligomerization of BAX and BAK on the OMM143,144. Furthermore, the
negatively charged headgroup of CL has a great binding affinity to Ca2+. The Ca2+-CL
neutralizing interaction consists an early step by which Ca2+ triggers OMM
permeabilization145.
Moreover, CL also regulates the activity and stability of the mitochondrial electron
transport chain respiratory complexes, ATP/ADP carrier proteins and import machineries
and the activity of dynamin-like GTPases that mediate mitochondrial membrane fusion
and fission140,146.
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How tethering of ER and mitochondria is regulated is
presently poorly understood. The GTPase Gem1 (GTPase
EF-hand protein of Mitochondria 1; MIRO (mitochondrial
Rho)-1 and-2 in mammalian cells) associates with ERMES
and is proposed to control the tethering of both organelles
in a GTP-dependent manner, perhaps in response to Ca2+
oscillations [42,44,45]. A proteomic study revealed ubiquitination of the ERMES subunit Mdm34 by the E3 ubiquitin
ligase Mdm30, but the physiological role of this modification remains to be determined [46]. Evidence for a role of
ubiquitination and ATP for lipid transfer to mitochondria
was obtained by analysing PS transport from the ER to the
mitochondria in a cell-free system. The E3 ubiquitin ligase
Met 30 was identified in a genetic screen for mutants
affecting PS transport to the mitochondria and shown to
ubiquitinate and destabilise the transcription factor Met4
[47]. Inactivation of Met4 leads to an increased transport of
PS from the MAM to the mitochondria, but the downstream target of Met4 remains to be identified. Thus,
multiple layers of regulation of ER–mitochondria contact
sites are emerging, but further studies are awaited to
define molecular mechanisms and the physiological significance of these regulatory circuits.
Intramitochondrial phospholipid trafficking
Role of contact sites between the OM and IM
After uptake into the mitochondria, phospholipids need to
be distributed between both mitochondrial membranes. In
46

negatively charged phospholipids such as CL than generally found in the OM or IM [49,50]. Proteomic studies as
well as genetic interaction maps allowed the identification
of a protein complex in yeast, termed MICOS (mitochondrial contact site), MINOS (mitochondrial inner membrane
organizing system) or MitOS (mitochondrial organizing
structure), that generates CS between mitochondrial membranes [51–53]. Loss of this tethering complex alters significantly the structure of the IM, which forms elongated
cristae membranes, while cristae junctions seem to be
absent. Deletion of the genes encoding subunits of this
complex cause strong growth defects when combined with
mutations affecting the CL biosynthetic pathway, linking
the function of contact sites between the OM and IM to the
biogenesis of phospholipids [53].

Ups/PRELI family proteins
Close membrane contacts between OM and IM may facilitate the spontaneous transfer of phospholipids between
both membrane bilayers (Box 2). Such a scenario, however,
renders the question how a different distribution of phospholipids between both membranes can be maintained.
The recent identification of conserved protein complexes
-20with lipid transfer activity in the IMS strongly suggests
that proteins promote the exchange of phospholipids between mitochondrial membranes.
Ups/PRELI proteins comprise a conserved protein family in eukaryotes, with several members present in most
organisms [54]. In yeast, three homologous proteins are

1.8 Mitochondrial Dynamics in Apoptosis and Tumor Invasion
Mitochondrial morphology is dynamically changed by fusion and fission in a
process known as mitochondrial dynamics. These morphological adaptations occur in
response to endogenous and exogenous stimuli and are essential in meeting the
energetic and physiological needs of the cells through production of ATP and
metabolites, but also the undesired byproduct of reactive oxygen species. ERMCs are
the major arena where these processes occur and the host both fusion and fission
players.
Fusion (Figure 1.8.1 A) is critical for maintenance of mitochondrial function and
inner membrane potential and is orchestrated by three large GTPases in the dynamin
family Mfn1, Mfn2 in the OMM and Opa-1 in the IMM147. Mfn1 is responsible for
mitochondrial docking and fusion, whereas Mfn2 coordinates the interactions between
mitochondria, and the stabilization of the whole mitochondrial network.
Proteins involved in both fusion and fission machinery also intersect apoptotic
pathways and vice versa (Figure 1.8.2). Several pro-apoptotic Bcl-2 proteins such as
Bax interact with Mfn2 and Mfn1148. Additionally the presence of Bax and Bak regulate
Mfn2 complex assembly, mobility and distribution on mitochondria149. Mitochondrial
fusion can delay cytochrome c release and apoptosis. Proapoptotic t-Bid disrupts Opa-1
oligomers and cristae remodeling required for cytochrome c release150, whereas Opa-1
deficient cells are more prone to apoptosis151.
Fission is especially important prior to mitosis to ensure the even distribution of
mitochondria to daughter cells and promotes mitochondrial membrane depolarization,
cytochrome c release and apoptosis (Figure 1.8.1 B). The fission process is mediated
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by dynamin-related GTPase, Drp1 to the OMM and involves post-translational
modification of Drp1 and its interaction with putative OMM receptors such Fis182,152. The
wrapping of ER tubules around constricted mitochondria where it forms ring-like
oligomers that pinch off mitochondria into smaller fragmented mitochondria153,154 is a key
early event in the mitochondrial division and prior to Drp1 recruitment.
Mitochondrial fission comprises an early even during apoptosis preceding
caspase activation and membrane blebbing. Fragmented mitochondria are more
amenable to Bax/Bak channel formation because DRP1 promotes Bax oligomerization
through mechanisms independent of its GTPase activity. Likewise, Drp1 associates with
OMM through Bax/Bak-dependent SUMO modifications of Drp1155.
Mitochondrial dynamics, or rather an imbalance toward fragmentation, are
determinants for tumor cell fate and can affect migration156–159, metastasis160,161 and
tumor progression162. Under therapeutic stress, cancer cells might undergo extensive
fusion to promote respiratory capacity and cell survival. Conversely, cancer cells
undergo mitochondrial fragmentation with alteration of DRP1 activity to repress oxidative
phosphorylation to prevent oxidative damage. Indeed, DRP1 activation and upregulation
is associated with mitochondrial fission across various malignancies156,160,163–165.
Correcting DRP1/MFN2 imbalances reduces in vitro cancer cell proliferation and
restores apoptosis166.
An indirect measure of mitochondrial dynamics in imaged cells is quantifying
mitochondrial morphology (roundness). The degree of fragmentation can be measured
by determining the ratio of long or branched mitochondria to round mitochondria167–169.
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Figure 1.8.2 Dual and opposing roles of Bcl-2 family members and fission/fusion proteins in
apoptosis and mitochondrial dynamics. Mitochondrial fission and fusion proteins appear to
modulate apoptosis through activities that are distinct from their roles in mitochondrial dynamics
but which involve members of the Bcl-2 family. Conversely, Bcl-2 family members modulate
mitochondrial fission and fusion in a manner that appears to be independent of their functions in
apoptosis (Boland et al., 2013).
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1.9 Guiding Hypothesis and Objectives
ER and mitochondria communicate at obligate contact sites that serve as critical
signaling hubs that regulate apoptosis, suggesting a potential role for inter-organelle
communication in cancer therapy resistance. Altered ER-mitochondria tethering has
been linked to neurodegeneration and diabetes suggesting regulation of this interorganelle contact may have broad relevance to human disease. In those pathologies
there is a gain-of-function, whereas in cancer we postulated there is a loss-of-function. I
posit that reduced ER-mitochondria tethering selected for in situ under
therapeutic stress leads to attenuated mitochondrial apoptosis and therapy
resistance (Figure 1.9). The overarching questions that guide these studies are: 1) Is
ER-mito tethering reduced in therapy resistant cancer cells compared to their therapy
sensitive counterparts? 2) Does altering (bidirectionally) ER-mito tethering affect stress
sensitivity or resistance as predicted? 3) What is the mechanism whereby reduced ERmito tethering leads to stress resistance? Could it be loss of essential calcium signals,
loss of lipid transfer, or both? Can ERMC function and therapy sensitivity be restored in
therapy resistance cancers?
I address these questions using high-risk neuroblastoma as a disease model.
This pediatric solid tumor shows a marked initial response to therapy with frequent
complete remissions before commonly recurring as a lethal MDR. My unique models
consist of pairs of tumor-derived cell lines obtained from the same patient at diagnosis
(DX) and again at relapse (REL) after selection in situ for multidrug resistance. I use an
innovative functional mitochondria BH3 profiling assay that quantifies mitochondrial
stress sensitivity. In this assay, mitochondria and their tethered ER membranes are
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isolated from tumor cells and probed with tBid or Bim peptides, terminal death effectors
downstream of therapeutic stress. Cytochrome c release is measured as a surrogate for
apoptotic commitment (mitochondria that undergo mitochondrial outer membrane
permeabilization (MOMP)). I used transmission electron microscopy and biophysical
organelle separation techniques to ascertain whether REL tumors have reduced ER-mito
content and tethering. Furthermore, I determine whether reduced ER-mito tethering
phenocopies therapy resistance in DX cells by genetic and biochemical manipulations.
Lastly, I assess ER-derived Ca2+ transfer in two patient DX/REL cell line pairs to
determine the impact of Ca2+ signaling on apoptotic sensitivity. I explore these questions
in Chapter 3 and summarize the findings and impending questions in Chapter 4.
TUMORS AT DIAGNOSIS (DX): RX SENSITIVE
● Therapy responsive
● MOMP sensitive
● Normal ER-mito tethering

TUMORS AT RELAPSE (REL): RX RESISTANT
● Therapy non-responsive
● MOMP incompetent
● Reduced ER-mito tethering

ER
ER

Bak/
Bax

Increased stress
(chemo & radiation therapy)

Cyto C
MOMP-competent (death)

MOMP-incompetent (survival)

Figure 1.9 Model of therapy resistance in neuroblastoma isogenic cell line pairs. At
diagnosis (DX), tumor mitochondria with functional ERMCs provide Ca2+ and lipid signaling to support
Bcl2 activation signals for MOMP. At relapse (REL), after the course of intensive multimodal therapy,
the ER and mitochondria lose their tethering, consequently becoming MOMP-insensitive.
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CHAPTER 2: METHODS
Cell Lines. Neuroblastoma cell lines were obtained from the COG/ALSF
Childhood Cancer Repository (www.CCcells.org). Cells were grown in IMDM Media
12440 (Life Technologies, Gaithersburg, MD) supplemented with 10% fetal bovine
serum, 2mM L-glutamine, 1% ITS, 100 U/ml of penicillin and 100 mcg/ml gentamycin.
Cell lines obtained at diagnosis (DX) were kept physically separate from those at relapse
(REL) at all times to avoid cross-contamination. Cell lines are referred to by name, often
with the descriptor “DX” or “REL” to note their time of derivation. All cell lines were
subjected to STR identity and pathogen testing every 4-6 months. Tissue culture
conditions were 37°C in a humidified atmosphere of 5% CO2. Cell lines were
interrogated for cancer gene mutations using the FoundationOne CDx assay
(Foundation Medicine) to confirm TP53, ALK and additional cancer gene mutation
status, including variant allele frequencies.

Isolation of Mitochondria-Enriched Heavy Membrane Fractions. Heavy
membrane fractions were obtained by rupturing cells resuspended in isolation buffer A
(250mM Sucrose, 20mM HEPES, 1mM DTT, 10mM KCl, 1mM EDTA, 1mM EGTA,
1.5mM MgCl2) with protease inhibitor cocktail by 20 strokes in a 2 mL glass Dounce
homogenizer, followed by removal of cell debris and nuclei by centrifugation of
supernatants at 800g for 10 min and then 1,050g for 10 min at 4°C. Mitochondriaenriched fractions were collected by centrifuging the supernatant of the second spin at
12,000g for 10 mins at 4°C.
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Magnetic Activated Cell Sorting (MACS) to Purify Mitochondria. To
physically separate MAMs from crude mitochondria, we used MACS according to
manufacturer’s MidiMACSTM Starting Kit (LS) protocol (130-042-301, Mitenyi Biotec,
Germany). Cells were collected in cold PBS and re-suspended in cold Buffer A with
protease inhibitor at the final concentration of 10 million cells/ml. After 20-25 strokes of
homogenization using a 7ml Dounce homogenizer, 1ml of cell lysate was mixed with 9ml
of ice-cold 1X Separation Buffer (130-091-221, Mitenyi Biotec) and incubated with 50µl
anti-TOM22 microbeads at 4°C on a shaker for 1 hour. The mixture was passed
stepwise through an LS column (130-042-401, Mitenyi Biotec), pre-rinsed with 3ml of 1X
Separation Buffer and installed in the magnetic field of the MidiMACS Separator (130042-302, Mitenyi Biotec). After washing three times with 3ml of 1X Separation Buffer, the
LS column was removed, and magnetically labeled mitochondria flushed into a collection
tube using 1.5ml of 1X Separation Buffer. Purified mitochondria were used immediately
for analysis or centrifuged at 13,000g for 2 minutes at 4°C and stored in 100µl storage
buffer on ice.

Mitochondrial Profiling. Heavy membrane or purified mitochondria cell fractions
were resuspended in buffer C [10 mM Tris-MOPS (pH 7.4), 1 mM KH2PO4, 10 mcM
Tris-EGTA, 5 mM glutamate, 2 mM malate, 125 mM KCl] at a final concentration of
1µg/µl. For cytochrome c release reactions, 50µl of mitochondria (1µg/µl protein) were
treated with Caspase-8-cleaved tBid from 5-500nM (882-B8-050, R&D Systems,
Minneapolis,

MN),

Bim-BH3

from

10-10,000nM

(Ac-

DMRPEIWIAQELRRIGDEFNAYYARR-amide; New England Peptide, Gardner, MA) or
300µM BidAltBH3 (Ac-EDIIRNIARHAAQVGASMDR-amide; New England Peptide, Inc.).
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Reactions were incubated at 37°C for 30 mins and spun at 12,000g for 10 min at 4°C:
10µl of the supernatant and the 10 µl pellet (mitochondrial) fractions were resuspended
in 50µl of 0.1% Triton X in PBS in duplicate in Quantikine, Human Cyto C Immunoassay
96-well plates followed by ELISA detection (R&D Systems, Minneapolis, MN). The
fractional release of mitochondrial cytochrome c was calculated for each condition as
[mean intensitysupernatant/(mean intensitymitochondria + mean intensitysupernatant)]. We report %
cytochrome c release normalized to the non-specific release induced by treatment with
DMSO (control) as [(fractional releasetreatment - fractional releasedmso)/(1-fractional
releasedmso)]*100. Experiments with <30% cytochrome c release to DMSO and
BidAltBH3 peptide were analyzed.

MAM/mitochondria Separation. Heavy membrane fractions were resuspended
in 2ml Isolation Medium (250 mM Mannitol, 5 mM HEPES pH 7.4, 0.5 mM EGTA, 0.1%
BSA) with freshly added protease inhibitors and slowly layered onto 8ml of 30% Percoll
gradient prepared with Gradient Buffer (225 mM Mannitol, 25 mM HEPES pH 7.5, 1 mM
EGTA, 0.1% BSA) in an Ultra-Clear Beckman Centrifuge Tube, and spun at 95,000g for
60 min to resolve MAM from more pure mitochondria, as described (29).

Cytotoxicity Assays. Cells were seeded into Corning® 96-well Flat Clear
Bottom White Polystyrene TC-treated luminescent microplates (3610, Corning, Corning,
NY) in triplicate at a density of 10,000 cells/well and allowed a 24 hour recovery period.
Cells were treated with 100ul of control GibcoTM IMDM full culture media (12440-053,
Gibco by Life Technologies, Carlsbad, CA). ABT-737 was tested from 1nM-200µM,
added to IMDM culture media for 48 hours. Chemotherapy exposure was 72 hours,
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concentrations tested were: etoposide (341205-25MG, EMD Millipore, Billerica, MA)
10nM-10µM, cisplatin (63323-103-51, Fresenius Kabi, Lake Zurich, IL) 0.5nM-75µM,
carboplatin (216100-25MG, EMD Millipore) 6nM-10µM, doxorubicin (5927S, Cell
Signaling Technology, Danvers, MA) 0.5nM-10µM, and masfosfamide (M110300
Toronto Research Chemicals, Inc, Toronto, Canada) 2nM-75 µM. ALK inhibitors
[crizotinib (C-7900, LC Laboratories, Woburn, MA), ceritinib (C-2086, LC Laboratories),
and lorlatinib (5640, Tocris Bioscience, Minneapolis, MN)] were tested from 0.01nM10µM and assessed after 5 days. Cells were irradiated on a Cs-137 Gammacell 40
irradiator S/N 186 (Nordion Ltd, Kanata, Ontario, Canada) at a dose rate of 1.3 cGy/sec
from 0.5 to 5 Gy and assessed after 7 days. Viability was assessed using CellTiter-Glo®
Assay according to the manufacturer’s instructions (Promega, Madison, WI; #G7571). A
Synergy™2 microplate reader with Gen5™ software (BioTek Instruments, Winooski, VT)
was used to measure luminescence. For each plate, mean relative luminescence was
calculated from at least three technical replicates, normalized to control samples.
Nonlinear regression algorithms in Prism software (GraphPad8) were used to calculate
IC50 values.

Real-time qPCR Detection of mtDNA. Mitochondrial DNA content was
quantified by qPCR to define the mtDNA/nucDNA ratio using each of two mitochondrialgenome (MT-C01 and MT-ATPase6) and two nuclear-genome (CFAP410 and MTTP)
genes. Assays were run in triplicate using Taqman Gene Expression Mastermix
(4369016, Applied Biosystems) and the following primer/probes from Invitrogen: MTCO1 (Hs02596864_g1), MT-ATPase6 (Hs02596862_g1), CFAP410 (Hs00223770_cn),
and MTTP (HS0405900_cn). mtDNA/nucDNA ratio was determined as the mean and SD
of all biological replicates.
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Citrate Synthase Measurements. Mitochondrial mass was assessed by
measuring citrate synthase activity from 4 million whole cells normalized to protein input
(U/mg) in triplicate from three biological replicates using the Citrate Synthase Assay Kit
(CS0720, Sigma-Aldrich, St, Louis, MO).

Electron Microscopy. Intact cells for electron microscopic examination were
fixed with 2% glutaraldehyde with 1% tannic acid in 0.1M sodium cacodylate buffer, pH
7.4, overnight at 4°C. After buffer washes, the samples were post-fixed in 2.0% osmium
tetroxide with 1.5% K3Fe(CN)6 for 1 hour at room temperature, and rinsed in ddH2O prior
to en bloc staining with 2% uranyl acetate. After dehydration through a graded ethanol
series, the tissue was infiltrated and embedded in EMbed-812 (Electron Microscopy
Sciences, Fort Washington, PA). Thin 70 nm sections were stained with uranyl acetate
and SATO lead and examined with a JEOL 1010 electron microscope (JEOL, Peabody,
MA) at 70 kV fitted with a Hamamatsu digital camera and AMT Advantage
NanoSprint500 software.

Measurement of MAMs, ER-mitochondria Gap Distances, and Mitochondria
Circularity and Roundness. TEM images at 50,000x magnification were analyzed
blinded in Image J by hand-masking the mitochondria perimeter and ER interface.
Analysis of the ER-mitochondria interfaces were extracted with a custom macro (65)
available at: http://sites.imagej.net/MitoCare/ that quantifies ER interface metrics binned
within a 10, 25, 50 or 100 nm gap distance from the mitochondria (34).
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Detection of ER-derived Ca2+ Transfer into Mitochondria. Mitochondriatargeted Ca2+ construct 4mtGCamp6f was electroporated into cells with with Amaxa
Nucleofactor (Lonza, Basel, Switzerland). Cells were allowed to recover in full IMDM
media for 24 hours and then plated on poly-D lysine covered slides, washed three times
with Ca2+-free HBSS medium (Life Technologies Inc., Grand Island, New York) and
loaded with 1µM Fura 2-AM (Life Technologies Inc., Eugene, OR) cytoplasmic Ca2+
indicator in the presence of 0.03% Pluronic F127 and 100µM sulfinpyrazone at 35 °C for
30 min. Fura-2AM-loaded cells were washed with Ca2+-free HBSS medium and mounted
into microscope loading chambers. Measurements of [Ca2+]m and [Ca2+]c were carried
out using a multiwavelength beamsplitter/emission filter combination and a high
quantum-efficiency cooled CCD camera. Excitation at 340 nm was used for Fura-2AM
and, 380 nm was used for 4mtGCamp6f. Basal fluorescent levels were measured for
120 ms, after which Ca2+ release from ER was evoked by addition of 100µM carbachol.
To determine the average [Ca2+]c and [Ca2+]m signals, mean fluorescence intensities
(ratios of Fura-2AM to 4mtGCamp6f) were calculated for essentially all individual wholecell areas in each run after subtraction of the background fluorescence measured at cellfree areas of the field. The Kd values of 340nm for Fura-2 AM and 380nm for GCamp6f
at 50% maximal release were used to calculate the coupling time.

Plasmids, Retroviral Constructs, and Reagents. A synthetic mitochondria-ER
linker was used to physically recouple ER and mitochondria, as described (34). Lentiviral
shRNAs to MFN2 (RHS5086-EG9927-GIPZ MFN2), PACS2 (RHS5086-EG23241-GIPZ
PACS2) and GIPZ non-silencing lentiviral shRNA Control were purchased from GE
Health Dharmacon, Inc., Lafayette, CO. 4mtGCamp6f was provided by Dr. Diego De
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Stefani. Primary antibodies: anti-BAP31 (ab109304, Abcam Inc, Cambridge, MA), anti-btubulin (T8328, Sigma-Aldrich, St. Louis, MO), anti-calnexin (C7617, Sigma-Aldrich),
anti-FACL4 (22401-1-AP, Proteintech, Rosemond, IL), anti-GAPDH (2118, Cell
Signaling Technologies, Danvers, MA), anti-𝛾-H2AX (NB100-384, Novus, Littleton, CO),
anti-MFN2 (ab56889, Abcam Inc), anti-MCU (HPA016480, Sigma-Aldrich), anti-noxa
(OP180, Calbiochem/EMD Chemicals, San Diego, CA), anti-PACS2 (ab129402, Abcam
Inc), anti-p53 (sc-126, Santa Cruz Biotechnology, Dallas, TX), anti-p21 (sc-6246, Santa
Cruz Biotechnology), anti-TMX1 (256-270, SAB1105403, Sigma-Aldrich), and antiTOMM40 (18409-1-AP, Proteintech, Rosemond, IL). To quantify protein knockdown,
densitometry was performed using ImageJ. The intensity of each band was normalized
to its respective loading control for comparison.

DNA Damage Detection. 10,000 cells were plated onto poly-L lysine coated
microscope slides, allowed to adhere 24 hours and irradiated at 2Gy for 1 hour on a Cs137 Gammacell 40 irradiator S/N 186 (Nordion Ltd, Kanata, Ontario, Canada) at a dose
rate of 1.3 cGy/sec. Cells were washed once with warm PBS and fixed with pre-warmed
paraformaldehyde for 10 minutes, permeabilized with 2% Triton-PBS for 5 minutes at
4°C, washed twice with PBS-5% triton and blocked for 10 minutes in Duolink blocking
solution. Cells were then incubated for 1 hour at 37°C with 𝛾-H2AX primary antibody
(NB100-384, Novus Biologicals, Centennial, CO) at 1:1000 dilution, washed twice with
PBS-T and incubated at 37°C with AlexaFluor goat anti-rabbit 488 (ab150077; Abcam
Inc, Cambridge, MA) at 1:500 dilution for at 45 minutes. After washing 4 times with PBST they were stained with VectaShield DAPI staining, covered with a microscope
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coverslip, and analyzed using a Leica DMR fluorescent microscope at 40X magnification
and the number of 𝛾-H2AX foci/cell quantified.

Statistical Analyses. Statistical comparisons for mitochondrial size, roundness,
circularity and MAM content per mitochondria were performed with the Mann-Whitney U
test, 2-tailed; comparisons for cytochrome c release, DNA damage foci, Ca2+-transfer
coupling time, mtDNA content and mass were performed with the student t-test,
independent values, two-tailed; comparisons for the proportion of mitochondria with
diverse tether numbers were performed using the Chi-Square test. For all, significance
was defined as p<0.05, trend p<0.10, and ns p≥0.10.

-34-

This chapter has been adapted from: Coku et al. Reduced ER-mitochondria connectivity
promotes neuroblastoma multidrug resistance. BioRxiv. March 1, 2021.
doi: https://doi.org/10.1101/2021.03.01.433120

CHAPTER 3: REDUCED ER-MITOCHONDRIA CONNECTIVITY
PROMOTES NEUROBLASTOMA MULTIDRUG RESISTANCE
Jorida Coku1, David M. Booth2, Jan Skoda3, Madison C. Pedrotty4, Jennifer Vogel5^,
Kangning Liu4, Annette Vu4, Erica L. Carpenter6, Jamie C. Ye4, Michelle A. Chen4&, Peter
Dunbar4@, Elizabeth Scadden4*, Eiko Nakamaru-Ogiso7,8, Yimei Li9, Kelly C. Goldsmith10,
C. Patrick Reynolds11,
Gyorgy Hajnoczky2, Michael D. Hogarty4,8#
Affiliations and addresses:
1
Cancer Biology Program, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, USA.
2
MitoCare Center, Department of Pathology, Anatomy & Cell Biology, Thomas Jefferson
University, Philadelphia, PA, USA.
3
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno,
Czech Republic.
4
Division of Oncology and Center for Childhood Cancer Research, The Children's
Hospital of Philadelphia, Philadelphia, PA, USA.
5
Department of Radiation Oncology, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, USA.
6
Department of Medicine, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, USA.
7
Mitochondrial Medicine Frontier Program, Division of Human Genetics, The Children's
Hospital of Philadelphia, Philadelphia, PA, USA.
8
Department of Pediatrics, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia PA, USA.
9
Department of Biostatistics, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, USA.
10
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
11
TTUHSC Cancer Center, Texas Tech University Health Sciences Center, Lubbock, TX,
USA.
Current Affiliations:
^
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins
University School of Medicine, Baltimore, MD, USA.
&
Howard University College of Medicine, Washington, DC, USA.
@
Departments of Pediatrics and Medicine, Brigham and Women’s Hospital, Boston, MA,
USA.
*Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.
Running Title: ER-mitochondria mediated cancer therapy resistance

-35-

Keywords: inter-organelle contacts; drug
membranes; calcium signals; neuroblastoma
#

resistance;

mitochondria-associated

Corresponding Author:
Michael D. Hogarty
Division of Oncology, The Children’s Hospital of Philadelphia
CTRB, Room 3020
3501 Civic Center Boulevard
Philadelphia, PA 19104-4318, USA
Phone: 215-590-3931
FAX: 215-590-3770
Email: hogartym@chop.edu
The authors declare no conflicts of interest exists.

-36-

3.1 ABSTRACT
Most cancer deaths result from progression of therapy resistant disease, yet our
understanding of this phenotype is limited. Cancer therapies generate stress signals that
act upon mitochondria to initiate apoptotic programs. We extracted mitochondria from
neuroblastomas obtained from children at diagnosis and again at relapse following failed
therapy, and profiled responses to tBid and Bim, principal death effectors activated by
therapeutic stress. Mitochondria from post-relapse tumors had markedly attenuated
mitochondrial outer membrane permeabilization in comparison with patient-matched
diagnostic tumors. Mitochondrial DNA content, size, and shape did not differ
consistently. However, physiochemical separation and electron microscopy identified
reduced endoplasmic reticulum-mitochondria contacts (ERMCs) as correlated with
therapy resistance. ERMCs form microdomains for the transfer of Ca2+ to mitochondria,
and we confirmed reduced Ca2+ transfer in resistant cells, and restoration of Ca2+
transfer by re-opposing ERMCs via genetically-encoded linkers. Reduced Ca2+ transfer
was not present in all ERMC-reduced cancers with therapy resistance, supporting Ca2+independent mechanisms. Genetically or biochemically reducing ER-mitochondria
coupling in therapy sensitive tumors phenocopied resistance, validating these interorganelle contacts as physiologic regulators of apoptosis. Our work confirms the
importance of ERMC in stress signaling and provides a previously unrecognized
mechanism for cancer cell resistance that is not exclusive to other contributors.
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3.2 INTRODUCTION
Over 600,000 people die of cancer each year in the US, most with progression of
disease that is resistant to available treatments, termed multidrug or therapy resistance.
Our understanding of the mechanisms underlying such broad resistance to diverse drug
classes and therapeutic modalities remains limited, but includes altered drug transport
into or out of the cancer cell, such as from increased activity of ATP-binding cassette
transporters (1), and mutations in genotoxic response genes like TP53 (2). The former
has not been confirmed to contribute to resistance in cancers in vivo and does not
explain resistance to drugs that are not substrates for such transporters, and the latter
does not explain therapy resistance in tumors with retained p53 activity and DNA repair.
More recently, the focus has shifted to studying resistance arising in response to
inhibitors of oncogenic kinases, with secondary mutations in the drug-target, activation of
bypass signals, and cellular plasticity identified as causal, yet even here a large
proportion of acquired resistance remains unexplained and seeking additional
contributors is warranted (3-8). In short, our lack of a more complete understanding of
the diverse contributors to therapy resistance remains a principal barrier to improving
cancer outcomes.
We used the highly lethal childhood tumor, neuroblastoma, as a model system to
investigate therapy resistance. Children with high-risk neuroblastoma are treated with
intensive chemoradiotherapy with stem cell rescue, surgery, retinoid therapy and
immunotherapy (9). Most patients have metastatic disease at the time of diagnosis yet
have chemosensitive disease that responds to treatment with significant tumor
regression, including complete responses. Despite this, half of all patients relapse with
lethal therapy resistant disease (10-12). To study emergent therapy resistance, we
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established tumor cell lines from the same patients at diagnosis prior to treatment, and
again at the time of relapse during or after treatment, providing near-isogenic tumor
models in which post-relapse tumors demonstrate therapy resistance acquired in situ
during exposure to multimodal therapy (10). Since mitochondria serve as platforms for
integrating cellular stress and survival signals in real-time, largely governed by Bcl2
family interactions, we hypothesized they harbor information related to therapeutic stress
sensitivity. We used an unbiased assay in which cancer mitochondria are probed with
tBid protein or BimBH3 peptides, death effectors activated downstream of most
therapeutic stress (13-16), to define their sensitivity for activating mitochondrial outer
membrane permeabilization (MOMP) as a surrogate for apoptotic commitment. We
discovered that mitochondria from therapy resistant tumors have markedly attenuated
MOMP responses in comparison with matched therapy sensitive counterparts,
demonstrating that mitochondrial apoptotic signaling dysfunction arises during the
course of clinical therapy and contributes to emergent multidrug resistance.
Many mitochondrial functions, including sensitivity to apoptosis, are regulated by
signals derived from endoplasmic reticulum (ER) at contact sites with mitochondria
[reviewed in (17, 18)]. Endoplasmic reticulum mitochondria contacts (ERMCs) are
supported by ER-mitochondrial tethers, and upon cell fractionation, give rise to
mitochondria-associated ER membranes (MAMs) that are enriched for specialized
protein bridges mediating inter-organelle communication. For simplicity, we use MAM to
refer to both ERMCs and MAMs in this paper. How cells regulate these contacts is
incompletely understood, however, the importance of MAMs in tuning the cross-talk
between these dynamic organelle networks is proposed to contribute to many
pathophysiologic states, such as diabetes, neurodegeneration, and cancer (19-22).
Here, we show that post-relapse tumor cell mitochondria have reduced MAM numbers
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and increased gap-distances, and these alterations are direct contributors to their stress
resistance, consistent with the multidrug resistance phenotype seen clinically. We show
this novel resistance phenotype contributes to resistance to chemotherapy, radiotherapy
and molecularly-targeted agents. Importantly, it is not exclusive to other resistance
mechanisms, but by acting downstream at a terminal signaling node imbues cancer cells
with resistance to diverse therapy-induced stressors that engage mitochondria. This new
framework for understanding therapy resistance may provide opportunities to enhance
cancer care, including the measurement of relative resistance by characterizing MAM
abundance and proximity, and enabling interventions to restore ER-mitochondrial
communication in resistant cancers.
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3.3 RESULTS
Mitochondria from drug resistant tumor cells have attenuated apoptotic
signal transduction. Optimizing approaches developed by Letai (23), we isolated
mitochondria from paired neuroblastoma cell lines derived from the same patients at
diagnosis (DX) before therapy, and at relapse (REL) during or after completion of
therapy (Figure 1A). Mitochondria-enriched heavy membrane fractions from tumor cells
were incubated with recombinant truncated-Bid or the death-activating BH3 domain
peptide of Bim (tBid and BimBH3, respectively) across a range of concentrations. Bid
and Bim proteins are direct-activators of intrinsic apoptosis liberated by diverse cell
stressors to either engage Bak or Bax to induce MOMP and cell death, or be
sequestered by pro-survival Bcl2-family proteins to neutralize their death signals (15,
24). The sensitivity for release of cytochrome c in response to tBid or BimBH3 reflects a
cell’s proximity to its apoptotic threshold (16, 25). By delivering terminal death effectors
directly to mitochondria, the assay bypasses the contributions of drug transport,
metabolism, target engagement and transcriptional response. Instead, mitochondrial
responses reflect the state of the Bcl2 family and related apoptosis-regulating processes
present in the tumor cell at the time of testing [reviewed in (26)]. A Bid BH3 domain with
substitution of two highly-conserved residues served as a negative control and induced
release of <10% of available cytochrome c in all experiments.

Seven DX/REL matched cell line pairs were studied, each pair tested
concurrently under identical culture conditions to minimize variability. Six of 7 pairs
showed attenuated cytochrome c release from tumor cells derived at relapse (Figure
1B-C; Supplemental Figure 1A). For 5 of the 7, REL mitochondria had reduced
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cytochrome c release in response to both tBid and BimBH3 in every biological replicate,
with both reduced sensitivity for release and reduced maximal release. One pair
demonstrated reduced cytochrome c release in response to BimBH3 peptide but not
tBid; and one pair (CHLA122/CHLA136) showed no consistent change as maximal
release differed <10% in all but one replicate. Overall, in 41 of 44 (93%) assays with tBid
or BimBH3, the mitochondria from post-relapse tumor cells released less cytochrome c
than their patient-matched counterparts from the time of diagnosis (Figure 1B).
Recombinant tBid was more potent at inducing cytochrome c release than BimBH3
peptide (all experiments), and maximal tBid-induced release exceeded that of BimBH3 in
39 of 42 (93%) experiments, despite BimBH3 peptide being used to >1 log higher
concentrations.

Relative cytochrome c release from tumor cell mitochondria was reproducible
(Figure 1C; Supplemental Figure 1). Mitochondria from CHLA15 (DX) and CHLA20
(REL) were profiled in 9 biological replicates with both tBid and BimBH3 and maximal
cytochrome c release for CHLA15 was greater than CHLA20 in all 18 experiments. The
SKNBE1(DX)/SKNBE2C(REL) and COGN144(DX)/COGN145(REL) pairs were profiled
in 4 biological replicates each, and DX tumor mitochondria released more cytochrome c
to both tBid and BimBH3 in all 16 experiments. In contrast, CHLA122 (DX) and
CHLA136 (REL) showed nearly equivalent cytochrome c release in 4 of 5 experiments
(in one, DX cells released >10% more cytochrome c than REL cells in response to
BimBH3). In all, maximal cytochrome c release in response to tBid or BimBH3 peptide
was significantly higher for DX tumor cells compared with patient-matched REL tumor
cells for the CHLA15/CHLA20, SKNBE1/SKNBE2C and COGN144/COGN145 pairs,
consistent with apoptosis resistance at relapse (Table 1). Overall, DX neuroblastomas
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released >50% of available cytochrome c in 38 of 43 of experiments (88%) using either
tBid or BimBH3 as a stimulus, whereas REL neuroblastomas released >50% in just 19 of
44 of experiments (43%), further reflecting their attenuated response to stress (p<0.01).
Only the CHLA122/CHLA136 pair demonstrated no difference in cytochrome c release in
response to tBid or BimBH3.

Cytochrome c release from isolated mitochondria correlates with tumor cell
sensitivity to diverse therapeutic stressors. Attenuated mitochondrial responses to
tBid and Bim, the stress sentinels activated by chemotherapy (13-16), predicts for
reduced cytotoxicity in response to such drugs. We compared sensitivity to
chemotherapeutics of different drug classes used to treat neuroblastoma, including
cisplatin, mafosfamide, etoposide and doxorubicin. Etoposide and doxorubicin are
substrates for the multidrug resistance protein, P-glycoprotein-1, whereas cisplatin and
mafosfamide are not. Both the CHLA15/CHLA20 and SKNBE1/SKNBE2C pairs that had
attenuated release of cytochrome c from REL mitochondria, showed relative
chemoresistance in REL tumor cells to both P-glycoprotein-1 substrates and nonsubstrates (Figure 2A; Supplemental Figure 2A; Table 1). In contrast, the
CHLA122/CHLA136 pair without attenuated mitochondrial release of cytochrome c did
not show differential chemosensitivity. Fold-resistance by comparing IC50 values for
DX/REL pairs were 1.6-fold to 33-fold for CHLA15/CHLA20 (3 of 4 drugs with >3-fold
difference); 4.2-fold to 122-fold for SKNBE1/SKNBE2C; and 1.2-fold to 2.6-fold for
CHLA122/CHLA136 (no drugs with >3-fold difference). We next assessed sensitivity to
ionizing radiation as a treatment modality to which there is less cross-resistance than
chemotherapy. Radiation bypasses drug transport and metabolism contributions to
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deliver genotoxic stress, which can be quantified as g-H2AX foci. SKNBE2C (REL) cells
had a larger induction of g-H2AX foci post-radiation (~10-fold compared with ~5-fold for
SKNBE1), yet they were 2-fold more radiation resistant (Supplemental Figure 3).
However, SKNBE2C cells harbor an acquired TP53 mutation (C135F) contributing to
their resistance, and fail to induce p53, p21 or noxa. CHLA20 (REL) cells, however, are
TP53 wild-type and were also >2-fold radiation resistant in comparison with CHLA15
(DX) cells despite both inducing p53 response genes and deriving equivalent DNA
damage, confirming attenuated apoptotic signaling downstream of radiation-induced
genotoxic damage (Figure 2B-C).

To determine whether attenuated mitochondrial responses also contribute to
resistance to molecularly targeted drugs, we tested Bcl2 inhibitors since their
mechanism of activity is localized at mitochondria. We previously showed that CHLA15
(DX) cells are sensitive to Bcl2 inhibitors as they use Bcl2 to sequester Bim and prevent
its activation of Bak or Bax (25). Both CHLA15 (DX) and CHLA20 (REL) cells have Bim
sequestered by Bcl2 and the Bcl2/Bclx inhibitor ABT-737 displaces Bim with equal
potency, yet CHLA20 cells are >40-fold more resistant despite the patient the cell line
derived from never having been treated with a Bcl2 inhibitor (IC50: CHLA15=260nM,
CHLA20=11.4µM; Figure 2D). In contrast, the CHLA122/CHLA136 pair also have Bim
sequestered by Bcl2, but these cells have similar mitochondrial responses and Bcl2
inhibitor responses (~1.8-fold IC50 difference). We did not test SKNBE1/SKNBE2C cells
with ABT-737 as they use Mcl1, rather than Bcl2, to neutralize Bim (25). We next studied
anaplastic lymphoma kinase (Alk) inhibitors since mutations in the ALK gene are found
in 10-14% of neuroblastomas and Alk inhibition has anti-tumor activity (27). Both
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CHLA15 (DX) and CHLA20 (REL) cells harbor an ALK R1275Q mutation (variant allele
frequency of 0.46 and 0.49, respectively). The patient this tumor pair was obtained from
had not been treated with an Alk inhibitor, yet REL cells were >3-fold more resistant to
the Alk inhibitors crizotinib, ceritinib and lorlatinib, without having a secondary
resistance-encoding

ALK

mutation

(e.g.,

crizotinib

IC50:

CHLA15=96nM,

CHLA20=349nM; Figure 2E). SKNBE1/SKNBE2C and CHLA122/CHLA136 have wildtype ALK and are resistant to Alk inhibitors (Supplemental Figure 2B). Therefore,
attenuated mitochondrial signaling that arises in response to multimodal therapy in situ
confers resistance to chemotherapy, radiotherapy, and molecularly-targeted drugs (the
latter in the absence of prior selective pressure). We next assessed the reverse: whether
selection for resistance to a molecularly targeted agent can induce this mitochondrial
phenotype. We exposed SH-SY5Y (ALK F1174L) and NB1643 (ALK R1275Q) cells to
escalating concentrations of crizotinib to generate crizotinib-resistant clones, and both
demonstrated attenuated MOMP responses to tBid and BimBH3 in the absence of
secondary ALK mutations, phenocopying REL cells (Figure 2F). In addition, such Alk
inhibitor resistant cells were more resistant to chemotherapy drugs such as etoposide
(>20-fold) and molecularly-targeted drugs like Bcl2 inhibitors (>40-fold; Figure 2G).

Attenuated mitochondrial apoptotic responses are accompanied by
reductions in ER-mitochondria associated membranes. We previously showed that
loss of Bak or Bax was unlikely to be a driver of attenuated MOMP as DX and REL cells
express abundant Bak and Bax protein (25). We next compared mitochondrial mass,
size, shape and mitochondrial DNA (mtDNA) content from DX and REL pairs, as these
have been correlated with apoptotic signaling in other systems. Mitochondrial mass
assessed by citrate synthase activity was unchanged in CHLA15 and CHLA20, and
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reduced in SKNBE2C (relative to SKNBE1) and CHLA136 (relative to CHLA122;
Supplemental Figure 4A). Mitochondrial DNA content was measured using
quantitative-PCR for two mitochondrial genes (MT-CO1 and MT-ATP6), each normalized
to two nuclear genes (CFAP410 and MTTP, disomic in >85% of neuroblastomas). TP53
mutant SKNBE2C cells had markedly reduced mtDNA content compared with TP53
wild-type SKNBE1 cells, consistent with p53 mutation effects on mtDNA content (28).
CHLA15/CHLA20 and CHLA122/CHLA136 pairs had less divergent mtDNA quantity with
modest reductions in REL cells at a subset of loci (Supplemental Figure 4B). We next
analyzed

transmission

electron

micrographs

to

assess

mitochondrial

size

(circumference) and shape (roundness and circularity; Figure 3A-C). These did not
differ for the SKNBE1/SKNBE2C and CHLA122/CHLA136 pairs, though there was a
trend toward larger mitochondria in SKNBE2C cells (p=0.06). The CHLA15 (DX) and
CHLA20 (REL) pair did differ, with REL cells having smaller more circular mitochondria
(p<0.01). Overall, these features did not correlate with mitochondrial cytochrome c
release sensitivity.

We used electron microscopy to visualize the mitochondria-enriched heavymembrane fractions tested in our mitochondrial profiling assays. Non-mitochondria
organellar membranes were abundant in all yet there was an increase in the proportion
of mitochondria in fractions from REL cells, despite their reduced cytochrome c release
when stimulated (Supplemental Figure 5A-B). ER is a major contributor to heavymembrane fractions, in particular, MAMs. We postulated that fewer ER-mitochondria
contacts leads to reduced MAM content in heavy-membrane fractions. To test this, we
fractionated heavy-membranes to resolve purified mitochondria from MAMs (29). With
equal cellular input, more MAMs were visualized from DX cells than REL cells for the
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CHLA15/CHLA20 and SKNBE1/SKNBE2C pairs, while the CHLA122/CHLA136 pair that
lacks attenuated mitochondrial signaling had slightly more MAM content in REL cells
(Supplemental Figure 5C). Consistent with this, Chipuk et al have shown in murine liver
and HeLa cells that separating mitochondria from MAMs using limiting proteolysis
reduces their release of cytochrome c in response to Bid and BimBH3 domains (30). We
also assessed ER-specific proteins in heavy-membrane fractions from DX and REL cells
but were unable to detect differential expression (Supplemental Figure 5D).

We next directly visualized MAM interfaces using transmission electron
micrographs of DX and REL tumor cells. We masked mitochondria and ER perimeters
and defined MAMs as regions of ER within 100 nm of the outer mitochondrial membrane
(OMM), and characterized their number, length and gap-width from the OMM, binned as
≤10 nm, 10-25 nm, 25-50 nm, and 50-100 nm (Figure 3D). CHLA20 (REL) cells had
reduced MAM content compared with CHLA15 (DX) cells (Table 1; Supplemental
Table 1). The number of MAMs per mitochondria was reduced (p<0.01), the frequency
of mitochondria with ≥2 MAMs was reduced while those absent MAMs were increased
(both p<0.01; Figure 3E; Table 1). Because CHLA20 mitochondrial had a mean
circumference 22% smaller (p<0.01), MAMs occurred at equal frequency in DX/REL
cells: every 1,651nm in CHLA15 and every 1,556nm in CHLA20. However, there was a
marked reduction in closely-apposed MAMs and MAM lengths in REL cells. The
proportion of MAM that came within 10nm of the OMM was reduced (p=0.05), as was
the proportion of the OMM perimeter in contact with a MAM at <10nm (Figure 3F; Table
1). In contrast, the proportion approximated by a MAM at larger gap-distances were less
reduced (Figure 3F). Similarly, SKNBE2C (REL) cells were reduced in the number of
MAMs per mitochondria compared to SKNBE1 (DX) cells (p<0.01), and the frequency of
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mitochondria with ≥2 MAMs was reduced, while those absent MAMs were increased >2fold (both p<0.01; Figure 3E; Table 1). MAMs occurred on average every 1,116 nm
along the OMM of SKNBE1 but only every 1,880 nm in SKNBE2C. In addition to
reduced frequency, the total length and proximity of MAMs were reduced in SKNBE2C
cells, adjacent to 24% of the mitochondrial perimeter in SKNBE1 but only 15% in
SKNBE2C cells, and MAMs were significantly reduced across all gap-widths (Figure 3F;
Table 1).

In contrast, CHLA136 (REL) cells do not have attenuated mitochondrial
responses, multidrug resistance, reduced MAM content by fractionation, nor reduced
MAM interfaces in comparison with CHLA122 (DX) cells (Figure 3E-F; Table 1). In fact,
CHLA136 (REL) cells had a trend toward more mitochondria with ≥2 MAMs (p=0.10) and
fewer orphan mitochondria (p<0.01), more MAMs per mitochondria overall (p=0.01), and
a slightly higher proportion of MAMs along the OMM across all gap-widths. The
characteristics of individual MAMs by their length and relative proximity to the
mitochondrial outer membrane were otherwise similar (Figure 3F). In all, reduced ERmitochondria connectivity (in particular, a reduction in the proportion of MAMs in close
proximity to the OMM) was recurrently present in tumor cells with multidrug resistance
and attenuated mitochondrial responses to death stimuli, nominating this feature as a
contributor to therapy resistance.

Reduced transfer of Ca2+ from MAMs to mitochondria is not required for
attenuated apoptotic signaling. MAMs support mitochondria as platforms to integrate
stress signals. They facilitate transfer of Ca2+ to mitochondria, which has been linked to
Bcl2-family functions and apoptotic sensitivity (31, 32). ER provides the major
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intracellular reservoir for Ca2+, and MAMs are enriched for Ca2+ release constituents to
create localized microdomains to enable Ca2+ transfer into mitochondria through the
mitochondrial calcium uniporter (mtCU) that has low Ca2+ affinity (32). The ensuing rise
in mitochondrial matrix calcium ([Ca2+]m) can promote apoptosis by either stimulating
permeability transition pore opening in the inner membrane or facilitating Bak and/or Bax
oligomerization and MOMP induction (33). Indeed, synthetically decreasing ERmitochondria tethering in rat liver cells and basophils leads to reduced Ca2+ transfer and
reduced apoptotic sensitivity, while augmenting tethering has been shown to increase
both (34).

We posited that the reduction in MAMs in REL tumor cells reduces ER-tomitochondria Ca2+ transfer to attenuate mitochondrial apoptotic signaling. To test this,
we measured Ca2+ transfer in two DX/REL pairs with differential MAM content.
Mitochondrial calcium concentration ([Ca2+]m) was detected with a fluorescent proteinbased Ca2+ sensor targeted to the mitochondrial matrix, GCamp6f. Cytoplasmic calcium
concentration ([Ca2+]c) was monitored with fura2 loaded to the cells as fura2AM. Calcium
responses evoked by the IP3R-linked stimulus, carbachol, were recorded and the timecourses for the corresponding fluorescence signals calculated. CHLA20 (REL) cells
have attenuated MOMP responses, multidrug resistant phenotype and reduced MAM
content in comparison with CHLA15 cells (DX), yet both have similar [Ca2+]c and [Ca2+]m
signals and coupling time (<2 seconds), the time difference between [Ca2+]c and [Ca2+]m
achieving 50% of maximum (Figure 4A). Like CHLA20, SKNBE2C (REL) cells also have
attenuated MOMP responses, multidrug resistant phenotype and reduced MAM content
in comparison with SNKBE1 (DX) cells. However, unlike CHLA20, SKNBE2C cells have
markedly reduced Ca2+ transfer compared with SKNBE1 (DX) cells, with a >3-fold
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increase in coupling time (p<0.01; Figure 4B). To confirm diminished Ca2+ transfer is
due to a reduction in MAMs, we genetically augmented MAMs in SKNBE2C cells using a
monomeric linker composed of a fluorescent protein extended with ER and OMM
membrane anchor domains (34). Linker-induced augmentation of MAMs normalized the
Ca2+ transfer coupling time to ~1.5 seconds, confirming the reduction was a
consequence of reduced ER-mitochondria contacts (Figure 4B). In both the
CHLA15/CHLA20 and SKNBE1/SKNBE2C pairs the REL cells showed similar
proportional reductions in MAM coverage at ≤10 nm ER-mitochondrial gap-width (Table
1). However, CHLA20 cells had preserved MAM coverage at larger gap-widths capable
of accommodating the Ca2+ transfer machinery, while SKNBE2C cells were reduced at
all gap-widths, limiting Ca2+ transfer.

We used biochemical and genetic approaches to further evaluate Ca2+ transfer
and stress sensitivity. We treated CHLA15 heavy-membrane fractions with Ru360, a
ruthenium red analog that inhibits the mtCU, before measuring cytochrome c release in
response to tBid or BimBH3. No reduction in release was seen (Figure 4D), nor was
cytochrome c release attenuated when treating whole cells short-term for 24 hours, or
longer-term for 7 days, before obtaining mitochondrial profiles (data not shown).
Similarly, CHLA20 (REL) cells did not have further attenuated cytochrome c release
following exposure to Ru360, although their release was reduced in comparison with
CHLA15, as expected. We next used siRNA to reduce expression of MCU, the poreforming component of the mtCU (35, 36). We first showed that MCU was not
differentially expressed in DX/REL pairs (Supplemental Figure 6A). MCU knockdown of
~45% and 60% was achieved in two CHLA15 subclones and MOMP sensitivity was only
modestly reduced (Figure 4E-F). We also tested MCU knock-down and Ru360 exposure
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in SKNBE1 cells and were unable to demonstrate a consistent reduction in cytochrome c
release in response to tBid or BimBH3 (Supplemental Figure 6B-D). Collectively, these
data support that reduced transfer of Ca2+ from ER to mitochondria is not required for
mitochondrial desensitization towards apoptotic MOMP.

The role of MAMs in mitochondrial apoptotic signaling can be functionally
demonstrated. Limited proteolysis to cleave ER-mitochondria protein bridges led to
reduced MOMP sensitization, however, it also induced >30% cytochrome c release
under control conditions, dampening the dynamic range of the assay. Immunomagneticbead separation (30) induced less membrane disruption, and MOMP sensitivity in
response to BimBH3 was greater for CHLA15 heavy membrane fractions (mitochondria
with intact MAMs) compared with purified mitochondria (reduced MAMs; Figure 5A).
SKNBE1 could not be assessed due to high release of cytochrome c release with either
separation process. While it may be difficult to abolish MAMs by genetic knock-down of
a single constituent of ER-mitochondria protein bridges, downregulation of phosphofurin
acid cluster sorting protein-2 (PACS2) or mitofusin-2 (MFN2) has been shown to reduce
MAMs (37-39). Mitochondria in CHLA15-shPACS2 cells with Pacs2 expression reduced
>50% were larger than CHLA15-shCtrl cells but similar in roundness and circularity
(Figure 5B-D). There was a trend toward reduced MAM per mitochondria though the
distribution of MAMs to mitochondria was preserved (Figure 5F; Table 2). MAM length
and proximity were reduced, with Pacs2 knock-down cells having a reduced MAM per
mitochondrial perimeter across all gap widths (Figure 5F-G; Table 2). The proportion of
MAM that came within 10nm or 25 nm of the OMM was reduced (p=0.02 and p<0.05,
respectively), as was the proportion of the OMM perimeter in contact with a MAM at all
gap-widths (Figure 5G). By comparison, mitochondria in CHLA15-shMFN2 cells with
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Mfn2 reduced ~60% had reduced circularity and roundness (p=0.03 and p<0.01,
respectively) but size was maintained (Figure 5B-E). There were fewer MAMs per
mitochondria (p<0.01), and the frequency of mitochondria with ≥2 MAMs was reduced
while those absent MAMs were increased (both p<0.01; Figure 5F). Moreover, MAM
lengths were reduced across all gap-widths (Figure 5G). We tested the sensitivity of
these cells to the Bcl2/Bclx-inhibitor, ABT-737, a pharmacological enhancer of MOMP in
CHLA15 cells, and knock-down of Mfn2 or Pacs2 phenocopied the ABT-737 resistance
seen in CHLA20 cells, shifting the IC50 >18-fold and 8-fold, respectively (Figure 5H). In
addition, CHLA15-shMFN2 cells, which had more substantial MAM alterations than did
CHLA15-shPACS2 cells, showed a resistance to tBid and BimBH3 in mitochondrial
profiles that phenocopied multidrug resistant neuroblastomas (Figure 5I).
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3.4 DISCUSSION
Most cancer deaths result from progression of disease that is resistant to
available therapies yet the principal contributors remain incompletely understood. The
diversity of targets and stress signals engaged by cancer treatments, and the myriad
adaptations cancer cells use to subvert them, pose fundamental challenges. One effort
to classify therapy resistance identifies mechanisms that reactivate, bypass, or induce
indifference to a drug-perturbed pathway (40). This model is most useful for resistance
to pathway-selective drugs, in particular, inhibitors of oncogenic kinases. Here we
identify a novel convergence-based mechanism of resistance arising from attenuation of
stress-induced MOMP as a consequence of reduced MAMs. Effective cancer therapies
activate stress signals that converge on mitochondria (23, 26, 41-44). Mitochondrial
sensitization toward MOMP is regulated through the activities of MAMs that serve as
essential contacts for the exchange of metabolites between ER and mitochondria. Since
mitochondria serve as a terminal node integrating stress signals to induce the death of
the cancer cell via MOMP, their attenuated responsiveness contributes to multidrug
resistance. Importantly, this mechanism is not exclusive to other contributors to therapy
resistance operative upstream of mitochondria.
We identified the MOMP-attenuated phenotype measuring mitochondrial
responses to the Bak and/or Bax activators, tBid and Bim. Mitochondrial profiling was
developed by Letai (23) and has been used to define Bcl2-family dependencies and
predict responses to chemotherapy (42-44) and molecularly targeted drugs (42, 45). We
optimized this for the study of neuroblastoma, a tumor that often responds to
chemoradiotherapy with tumor regression (46) followed by lethal relapse (12). Limited
availability of paired clinical samples has constrained such investigations, so we derived
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patient-matched tumor models at both diagnosis and relapse, the latter frequently
manifesting multidrug resistance (10). Cell lines were used as they can be established
under identical conditions from tumor biopsies, or from tumor-involved bone marrow, the
latter the most common source at relapse. We show that mitochondria from relapsed
neuroblastomas have markedly reduced MOMP responses to tBid and Bim (14)
compared with their at-diagnosis counterparts, providing evidence that attenuated
mitochondrial signaling is acquired under the selective pressure of multimodal therapy.
Attenuated MOMP was reproducibly identified in nearly all relapsed neuroblastomas in
response to either death-activator, although tBid was more potent than BimBH3. Indeed,
BimBH3 is an intrinsically unstructured peptide (47) that typically engages Bak or Bax at
micromolar exposures, while recombinant tBid protein binds lipid membranes to activate
Bak or Bax at nanomolar exposures, highlighting the important role of lipid membranes
in facilitating MOMP (15, 48). Quantitative variability among biological replicates were
notable, reflecting myriad events impinging on Bak/Bax-mediated pore formation,
including temperature, pH, detergents and metabolites (49). Working with patientmatched pairs in parallel controlled for many of these variables and relative differences
between tumors were robust.
Our work utilized neuroblastoma cell lines that represent oligoclonal outgrowths
from explanted tumors. If MOMP sensitivity were highly heterogeneous within a tumor,
we would predict some diagnosis-relapse pairs to have attenuated mitochondrial
responses present at diagnosis. Instead, our data support that contributions from intratumoral heterogeneity are minor in comparison with the effect of therapeutic selective
pressure. We confirmed that attenuated mitochondrial responses correlated with
resistance to chemotherapy and ionizing radiation. For the latter, differential cell death
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follows equivalent genotoxic stress supporting a post-target resistance mechanism.
Resistance is also conferred to molecularly targeted drugs such as Bcl2 and Alk
inhibitors, even in the absence of prior exposure, since these operate upstream of
mitochondria. More surprising, however, is evidence that selecting for resistance to such
target-selective agents in vitro can induce the attenuated MOMP phenotype
accompanied by multidrug resistance. This provides a potential mechanism for the
significant proportion of patients with emergent resistance to therapeutic kinase
inhibitors that have no on-pathway resistance mechanism identified (3-6, 8), a clinically
relevant finding. That mitochondrial responses can discriminate chemosensitive from
chemoresistant tumors has been shown using similar approaches (43), which also
demonstrate a mitochondrial basis for the selective killing of tumor cells by
chemotherapy (26, 44). Here, we expand this notion to demonstrate a mitochondrial
basis for multidrug resistance in response to therapeutic pressure during multimodal
therapy.
We identified reductions in MAM content from tumors with attenuated MOMP
when visualized by fractionation or quantified in electron micrographs. ER-mitochondria
contacts at MAMs regulate fission/fusion dynamics to optimize mitochondrial shape (50),
which impacts Bax-induced MOMP in murine hepatocytes and murine embryo
fibroblasts (MEFs) by altering cooperation among Bcl2-family members. Smaller
mitochondria with increased membrane curvature are more resistant to stress-induced
MOMP (51), and are capable of promoting incomplete-MOMP followed by mitochondrial
re-population and cell survival following stress (52), possibly contributing to
chemoresistance (51). Consistent with this, the CHLA15/CHLA20 pair had smaller more
circular mitochondria in the post-relapse MOMP-resistant tumor, however, this was
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absent in SKNBE1/SKNBE2C (in which mitochondria in the relapsed model were larger).
While mitochondrial size, shape, mass and mtDNA content differed variably, only the
reduction in MAM content and ERMCs was consistently present across models with
attenuated mitochondrial responses, while absent in the sole pair without this feature.
Our image analyses were done in two dimensions yet inter-organelle contacts
occur in 3D, so to ensure representative findings we quantitatively analyzed >2,400
MAMs from >1,700 mitochondria across 9 tumor models. In both the CHLA15/CHLA20
and SKNBE1/SKNBE2C pairs, the ER-mitochondrial connectedness was markedly
reduced in the therapy resistant post-relapse model, with significantly more orphan
mitochondria and fewer mitochondria with ≥2 MAMs. Moreover, the proportion of
mitochondrial surface with an apposed MAM was reduced. In contrast, the only tumor
pair without attenuated MOMP responses or chemoresistance, CHLA122/CHLA136, did
not have such alterations. That MAMs might be reduced in cancer cells was originally
posited by Howatson and Ham from EM studies of mouse liver tumors (53). An essential
role for MAMs in mediating apoptotic sensitivity has been demonstrated by Chipuk et al
(30). Using MEF heavy-membrane mitochondria-enriched fractions, they showed that
MOMP sensitivity to Bid peptides was attenuated when mitochondria were purified from
their associated MAMs, and rescued by the add-back of MAM-containing heterotypic
membranes (30). Consistent with this, we could phenocopy attenuated MOMP
responses by reducing MAMs from mitochondria in diagnostic-tumors using chemical
proteolysis or genetic perturbation. In the latter, we confirmed that a MAM-reduced
phenotype was achieved using EM image analysis.
Collectively, these data support an essential factor for mitochondrial sensitization
to MOMP is provided by MAMs. Korsmeyer’s group showed that many intrinsic cell
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death signals require both functional Bak or Bax and ER-released Ca2+ (54) and
deficiencies in MAM-derived Ca2+ transfer can confer apoptosis resistance in
mesothelioma cells (55). We found a >3-fold increase in Ca2+ transfer coupling time in
therapy resistant SKNBE2C (REL) cells compared with DX cells, which was normalized
using a genetic linker to tighten MAM contacts. However, we found no change in
coupling time for the CHLA15/CHLA20 pair. Our EM analyses provide a potential
explanation as CHLA20 has MAM reductions more limited to tighter gap-widths with
relative preservation at larger gap-widths capable of creating Ca2+ transfer microdomains
(34, 56). While altered Ca2+ transfer may contribute to MOMP regulation, it is not
indispensable for the attenuated MOMP sensitivity in relapsed neuroblastoma. While
narrow gap-width MAMs are unable to accommodate the Ca2+ transfer machinery, such
close contacts are critical for phospholipid transport. MAMs are enriched in lipid
synthesizing enzymes, mitochondria are dependent on ER-derived lipid transport, and
the composition of mitochondrial membranes is a determinant of MOMP sensitivity.
Chipuk and Green demonstrated that the reduced MOMP sensitivity of mitochondria
isolated from MAMs can be restored by the return of MAMs themselves, or by the
provision of sphingosine-1-phosphate or hexadecenal, which support Bak or Bax
oligomerization (30). Indeed, such tight contacts (<10 nm) have been referred to as lipidERMCs, reflecting this essential role (57, 58), and reductions have been associated with
altered mitochondrial lipid composition in neurons in Alzheimer models (57). It is
intriguing to speculate that reduced MAMs contribute to stress resistance in cancer cells
by altering the mitochondrial OMM sphingolipid environment to attenuate Bak and Bax
responsiveness, and further investigation is warranted (59).
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We propose that MAMs serve as physiological regulators of apoptosis in cancer
cells and that MAM reductions comprise an adaptive response to therapeutic stress,
providing a novel mechanism for multidrug resistance involving disrupted ERmitochondria communication (Figure 6). During cancer therapy, cells with reduced
MAMs have a higher survival probability via “incomplete-MOMP” (52) leading to
selective enrichment. Alterations in MAMs have increasingly been linked to diverse
pathological states, including cardiomyocyte recovery after re-perfusion (60), ototoxic
injury (61), neurodegeneration (20-22, 62, 63), and obesity-related diabetes (19, 64).
Moreover, our attenuated MOMP model proposes that multidrug resistance does not
reflect an absence of activated death signals but their insufficiency to trigger MOMP.
Investigational cancer drugs are first tested in patients with multidrug resistance
following failed therapies. For the many drugs that do not induce a tumor response in
such studies, we cannot differentiate those that effectively engaged their target and
liberated death-activating signals (that remained subthreshold) versus those that did not,
leading investigators to abandon some drugs that might have clinical efficacy in other
settings. Importantly, recognizing this phenotype can facilitate the development of tools
to measure ER-mitochondria interactions for clinical use in predicting therapy resistance,
and provides a novel framework for testing interventions to prevent emergent resistance
or restore mitochondrial competence to resistant cancers.
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Figure 1. Mitochondria from neuroblastomas obtained at relapse have attenuated
apoptotic responses. (A) Tumor models were derived from the same children with
neuroblastoma both at the time of diagnosis and again at relapse following treatment.
Mitochondria-enriched heavy membrane fractions were isolated and exposed to the deathactivating stimuli, tBid or BimBH3 peptide, across a range of concentrations. Release of
cytochrome c is measured as a surrogate for MOMP and apoptotic commitment. (B) Mitochondria
derived from post-relapse tumors (REL) show attenuated maximal cytochrome c release in
response to tBid or BimBH3, in comparison with patient-matched tumors from the time of
diagnosis (DX) prior to therapy. (C) Maximal release for DX/REL pairs is shown for each
biological replicate (connected by line), demonstrating reproducible attenuated cytochrome c
release for most diagnosis-relapse pairs. As apparent from the box plots summarizing individual
replicates, only the CHLA122/CHLA136 pair have equivalent cytochrome c release. MOMP,
mitochondrial outer membrane permeabilization; PDX, patient-derived xenograft; cyto c,
cytochrome c.
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Figure 2. Post-relapse neuroblastomas are resistant to multiple chemotherapeutics,
molecularly targeted drugs, and radiotherapy. (A) Chemotherapy resistance to diverse agents
is present in post-relapse CHLA20 and BE2C cells (with attenuated mitochondrial responses)
compared with patient-matched at-diagnosis (DX) tumors, whereas post-relapse CHLA136 cells
(without attenuated mitochondrial responses) are not chemoresistant. (B-D) Radiotherapy
induces p53 response genes and equivalent DNA-damage as measured by g-H2AX foci in both
CHLA15 (DX) and CHLA20 (REL) cells but REL tumor cells are >2-fold more resistant to
undergoing cell death. (E) Similarly, CHLA20 cells are resistant to the Bcl2/Bclx-inhibitor, ABT737, and the ALK inhibitor, crizotinib, despite this patient never having received either class of
drug. (F-G) Reciprocally, at-DX tumor cells made resistant to the ALK inhibitor, crizotinib, through
exposure to escalating in vitro concentrations, manifest a similar attenuated mitochondrial
response phenotype, along with emergent resistance to chemotherapy (etoposide) and targeted
drugs (ABT-737) that this phenotype predicts. DX, diagnosis; REL, relapse.
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Figure 3. Post-relapse therapy resistant neuroblastomas have reduced mitochondriaassociated membranes compared with patient-matched tumors from diagnosis.
Transmission electron microscopy (TEM) image analysis identified no consistent changes in
mitochondrial size (A), circularity (B) or roundness (C) that correlated with attenuated
mitochondrial responses or therapy resistance. (D) Electron micrograph mockup illustrating
organelle masking and characterization of MAM interface metrics. (E) Image analyses of ERmitochondria contacts show a higher proportion of mitochondria with few (0-1) tethers and a lower
proportion with higher numbers of tethers in tumor models with attenuated mitochondrial
responses and therapy resistance (CHLA20 and BE2C), whereas this change was absent in the
CHLA122/CHLA136 pair that did not manifest such resistance. (F) Similarly, the percentage of
the mitochondria perimeter with an apposed ER within defined gap-widths (defining MAMs) were
reduced in CHLA20 and BE2C compared with their respective patient-matched at-diagnosis
models, whereas the CHLA122/CHLA136 pair did not manifest this change. DX, diagnosis; REL,
relapse.
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Figure 4. Reduced calcium transfer between ER and mitochondria is not required to
attenuate mitochondrial responses to therapeutic stress. ER to mitochondria Ca2+ transfer
can be assessed by measuring cytosolic (black-tracing) and mitochondrial (blue-tracing for DX
model, red-tracing for REL model) calcium concentration following inositol trisphosphate receptor
(IP3R) agonist-induced release of ER calcium stores, triggered with 100 µM carbachol exposure.
The coupling time (time between achieving 50% of maximal cytosolic and 50% of maximal
mitochondrial calcium concentrations) is an index of ER-mitochondrial proximity and transfer
efficiency. (A-B) Coupling time is equivalent in CHLA20 (REL) and CHLA15 (DX) cells, and
significantly prolonged in BE2C (REL) compared with BE1 despite both REL models manifesting
attenuated mitochondrial responses and therapy resistance. (C) To confirm that the increased
coupling time reflects reduced MAM proximity, MAM tightening was enforced using an ERmitochondrial linker construct. The prolonged coupling time evident in BE2C cells was
recapitulated in BE2C cells expressing an OMM control linker, while coupling time was
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normalized by use of an ER-mitochondrial linker to enhance MAM proximity. (D) Treatment of
mitochondria-enriched heavy membrane fractions of CHLA15 and CHLA20 with Ruthenium-360
(Ru360) does not affect mitochondrial release of cytochrome c in response to tBid or BimBH3. (E)
Silencing of the mitochondrial calcium uniporter (MCU) was achieved in two different CHLA15shMCU clones with ~60% and 45% reductions in protein level. Cytochrome c release in response
to tBid was not altered, however, BimBH3 responses were mildly reduced compared to shCtrl
cells though this was not proportional to the extent of MCU knock-down (F). OMM, outer
mitochondrial membrane.
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Figure 5. Attenuating MAM content leads to mitochondrial apoptosis resistance. (A) Heavy
membrane (HM) fractions of mitochondria rendered MAM-depleted by proteolytic and immunemagnetic cell sorting (pMito; purified mitochondria) show attenuated cytochrome c release in
response to BimBH3 relative to HM fractions. (B, C, D) Mitochondrial morphological changes
include decreased circularity and roundness for CHLA15 cells with reduced MFN2 (shMFN2) and
decreased mitochondrial size for CHLA15 cells with reduced PACS2 (shPACS2). (E) Immunoblot
analysis show 62% MFN2 protein reduction and 53% PACS2 protein reduction in shMFN2 and
shPACS2 cells, respectively, in comparison to non-target shRNA control cells. (F, G) Both
CHLA15-shMFN2 and CHLA15-shPACS2 cells have reduced numbers of MAMs per
mitochondria and decreased percentage of the mitochondria perimeter with an apposed ER
within defined gap-widths (defining MAMs). (H) CHLA15-shMFN2 and CHLA15-shPACS2 cells
have enhanced resistance to ABT-737, with >18-fold increased IC50 for shMFN2 (from 0.76 µM
to 14.2 µM) and >8-fold increase for shPACS2 (6.3 µM); phenocopying resistance seen in REL
CHLA20 cells (7.9 µM), reflected also in diminished responses of mitochondrial to tBid and
BimBH3 in CHLA15-shMFN2 cells (but not seen in CHLA15-shPACS2 cells (I).
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Figure 6. MAM-mediated mitochondrial resistance model. At diagnosis (DX), neuroblastoma
cells typically have MAM-replete mitochondria that are MOMP competent, and are relatively
sensitive to chemotherapy, radiation therapy, and targeted agents like ALK inhibitors and Bcl2
inhibitors. Relapsed (REL) tumors recurring after multimodal therapy frequently have cells with
reduced MAMs (by number and/or proximity to mitochondria) and are relatively multidrug
resistant as a consequence of mitochondria that have attenuated MOMP in response to stress
signals such as tBid or Bim (red box). Rare tumors at relapse retain MOMP competence and
threrapy sensitivity (green box). Calcium transfer from ER to mitochondria may be reduced when
MAMs are markedly attenuated at smaller gap-widths that enable efficient calcium transfer, but
this reduced transfer is not essential for the multidrug resistant phenotype.
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Figure S1. Reduced cytochrome c release from mitochondria in response to stress signals
is a recurrent characteristic of relapsed neuroblastomas. The major therapy-induced stress
signals, tBid and Bim (here recapitulated by the death-domain peptide itself, BimBH3), capable of
triggering MOMP in isolated tumor mitochondria through the activation of Bak and/or Bax. (A)
Heavy-membrane mitochondria-enriched fractions were isolated from tumors at the time of
diagnosis (DX, blue curves), and from the same patient at the time of relapse after failed
multimodal therapy (REL, red curves). Each plot represents a biological replicate experiment in
which cytochrome c release represents the mean of 3 technical replicates. Model pairs that
expanded readily and had spontaneous release of cytochrome c of <30% of that available (in
response to control buffer or a death-domain inactivated BimBH3) were repeatedly assayed to
demonstrate reproducibility, as shown. The CHLA122/CHLA136 pair did not demonstrate
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attenuated mitochondrial responses to tBid or BimBH3 in serial assays so was included in our
mitochondrial characterization assays as a control pair, along with CHLA15/CHLA20 and
BE1/BE2C as pairs manifesting profound mitochondrial response attenuation. (B) A similarly
attenuated cytochrome c release in response to tBid or BimBH3 was seen from heavy-membrane
mitochondria-enriched fractions obtained from neuroblastoma cells selected for resistance to the
Alk inhibitor, crizotinib (both SY5Y and NB1643 harbor activating ALK mutations sensitizing cells
to crizotinib and other Alk inhibitors). Cells with crizotinib resistance are designated by “-ALKR”
and are shown relative to parental crizotinib sensitive cells.
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Figure S2. Most post-relapse neuroblastomas are resistant to multiple chemotherapeutics
and molecularly targeted drugs. (A) Chemotherapy resistance to cisplatin and etoposide is
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Figure S3. Post-relapse neuroblastoma cells are resistant to the cytotoxic effects of
ionizing radiation despite incurring an equivalent increase in DNA damage. BE1 (DX) and
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Figure S4. Neuroblastoma DX/REL pairs have altered mitochondrial biomass and/or
morphology, but no consistent change is correlated with attenuated mitochondrial
responses to stress or with chemotherapy resistance. (A) Mitochondrial biomass as
assessed by citrate synthase activity across at-diagnosis (DX) and post-relapse (REL) pairs
normalized to total protein input (IU/mg) reveals reduced mitochondrial biomass in BE2C
(resistant) cells and CHLA136 (sensitive) cells, compared with their patient-matched DX tumor
cells, but no change in the CHLA15/CHLA20 pair (also resistant). (B) Mitochondrial DNA content
as quantified by qPCR using the mtDNA/nucDNA ratio for each of two mitochondrial-genome
(MT-C01 and MT-ATPase6) and two nuclear-genome (CFAP410 and MTTP) genes. REL tumor
cells showed minor reductions in mitochondrial DNA content compared with DX cells for
CHLA15/CHLA20 (in 1 of 4 comparisons) and CHLA122/CHLA136 (in 3 of 4 comparisons), and
more marked reductions in BE1/BE2C (4 of 4 comparisons). The more extensive reduction in
mitochondrial DNA in BE2C is likely a consequence of mutant p53 signaling, as this has been
reported in other cancer cell lines.
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Figure S5. Evidence for reduced mitochondria-associated membrane (MAM) content in
neuroblastomas obtained at the time of relapse in comparison to at-diagnosis tumors. (A)
Images of electron micrographs of heavy-membrane mitochondria-enriched fractions from
CHLA15 and CHLA20 crude cells identified proportionately more mitochondria by unit volume in
post-relapse CHLA20 cells, despite this fraction having markedly diminished mitochondrial
responses to stress signals (see Figures 1 and S1); graphically represented in (B). (C) Heavymembrane fractions were obtained from equal biomasses of cell input, and further separated by
Percoll gradient ultracentrifugation into MAM fractions and purified mitochondria. Such
physiochemical separation identifies reductions in MAM content in both post-relapse (REL)
CHLA20 and BE2C cells compared with their diagnostic (DX) counterparts. In contrast, CHLA136
(REL) cells did not have reduced MAM content, nor do they manifest attenuated mitochondrial
responses or chemoresistance. (D) Immunoblot detection of various MAM- and ER-localized
proteins from heavy-membrane mitochondria-enriched lysates in DX and REL tumors fail to
demonstrate significant changes recurrently among DX/REL pairs.
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Figure S6. Attenuating transfer of calcium from ER to mitochondria does not significantly
attenuate mitochondrial stress responses. (A) Immunoblot detection of MCU (mitochondrial
calcium uniporter) expression across patient-matched pairs of at-diagnosis (DX) and post-relapse
(REL) neuroblastomas show no significant alterations, even in BE2C cells that have reduced
calcium transfer (see Figure 4). (B). MCU silencing in BE1 cells using two different shRNA
hairpins led to subcloning of a line with ~33% reduction in MCU at the protein level (BE1shMCU#5), yet this change does not alter mitochondrial cytochrome c release in response to
tBid, or BimBH3 (C) compared to control BE1 cells. (D) Similarly, pretreatment of heavymembrane mitochondria-enriched fractions of BE1 cells with a 30-minute exposure to the MCU
inhibitor, Ruthenium-360, does not attenuate mitochondrial apoptotic sensitivity.
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Table 1. Summary of paired diagnostic (DX) and relapse (REL) neuroblastoma
models.
Table 1. Summary of paired diagnostic (DX) and relapse (REL) neuroblastoma models.
MITOCHONDRIAL
RESPONSE:
Max % cyto c release, tBid
(mean +/- sd)
Max % cyto c release,
BimBH3 (mean +/- sd)

CHLA15

CHLA20

78 ± 8

53 ± 19

63 ± 13

31 ± 12

SKNBE1

SKNBE2C

p<0.01

85 ± 7

59 ± 11

p<0.01

68 ± 14

40 ± 7

CHLA122

CHLA136

p<0.02

77 ± 5

78 ± 1

p= ns

p<0.02

66 ± 6

62 ± 4

p= ns

TUMOR CELL RESPONSE
(fold-resistance, IC50):
Mafosfamide

3.9

12.9

1.2

Doxorubicin

33.0

28.6

1.7

Cisplatin

1.6

4.2

2.6

Etoposide

3.5

122.0

2.1

Ionizing Radiation

2.1

2.0

n.d.

Crizotinib

5.0

n.d.

ABT737

44.0

n.d.

n.d.
1.8

MITOCHONDRIA:
Number analyzed

196

241

Perimeter, mean (nm)

2,207

1,725

Perimeter, median (nm)

2,055

1,675

p<0.01

137

160

1,653

1,810

1,503

1,725

p=0.06

206

143

1,626

1,454

1,404

1,330

p= ns

Circularity, median

0.902

0.920

p<0.01

0.910

0.898

p= ns

0.913

0.905

p= ns

Roundness, median

0.996

0.745

p= ns

0.714

0.692

p= ns

0.676

0.655

p= ns

% with 0 MAMs

18%

32%

p<0.01

18%

40%

p<0.01

17%

8%

% with 1 MAMs

39%

39%

37%

35%

33%

34%

% with 2-3 MAMs

41%

25%

38%

22%

42%

43%

% with ≥4 MAMs

3%

3%

6%

4%

7%

15%

%OMM with MAM gap-width
≤10 nm
%OMM with MAM gap-width
≤25 nm
%OMM with MAM gap-width
≤50 nm
%OMM with MAM gap-width
≤100 nm

0.7%

0.4%

(↓43%)

2.3%

1.1%

(↓52%)

2.1%

2.7%

(↑29%)

2.5%

2.1%

(↓16%)

6.0%

3.5%

(↓42%)

6.1%

6.8%

(↑11%)

6.8%

6.3%

(↓7%)

12.4%

7.6%

(↓39%)

12.8%

14.2%

(↑13%)

16.9%

15.5%

(↓8%)

24.4%

15.2%

(↓38%)

24.0%

25.5%

(↑6%)

203

154

334

386

p<0.01

1.48

0.96

p<0.01

1.62

2.00

1,116

1,880

710

1,134

p<0.01

p<0.01

p<0.01
(REL fewer)
p= ns

MAM:
Number analyzed

267

266

MAMs per mitochondria

1.36

1.10

MAM frequency (per nm
perimeter)

1,651

1,556

%MAM with gap-width ≤10
nm
%MAM with gap-width ≤25
nm
%MAM with gap-width ≤50
nm
%MAM with gap-width ≤100
nm

18%

12%

p=0.05

30%

21%

p<0.01

36%

39%

p= ns

40%

36%

p= ns

57%

46%

p<0.01

65%

69%

p= ns

70%

63%

80%

73%

86%

93%

100%

100%

100%

100%

100%

100%
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p=0.01
(REL more)

Table 2. Summary of CHLA15-Ctrl (DX) and CHLA15-shMFN2 and -shPACS2
models.
Table
2. Summary of CHLA15-Ctrl (DX) and CHLA15-shMFN2 and -shPACS2 models.
CHLA15ctrl

CHLA15shMFN2

CHLA15shPACS2

MITOCHONDRIA:
Number analyzed
Perimeter, mean (nm)
Perimeter, median (nm)
Circularity, median
Roundness, median

214
1,416
1,319
0.918
0.715

234
1,468
1,381
0.892
0.655

% with 0 MAMs
% with 1 MAMs
% with 2-3 MAMs
% with ≥4 MAMs

19%
37%
37%
6%

33%
39%
26%
1%

p<0.01

%OMM with MAM gap-width
≤10nm
%OMM with MAM gap-width
≤25nm
%OMM with MAM gap-width
≤50nm
%OMM with MAM gap-width
≤10n0m

1.7%

0.9%

5.9%

p= ns
p=0.03
p<0.01

246
1,530
1,453
0.914
0.686

p<0.01
p= ns
p= ns

24%
39%
22%
5%

p= ns

(↓47%)

1.0%

(↓41%)

3.0%

(↓49%)

3.5%

(↓41%)

12.6%

7.8%

(↓38%)

9.3%

(↓26%)

27.4%

17.8%

(↓35%)

21.2%

(↓23%)

MAM:
Number analyzed
MAMs per mitochondria
MAM frequency (per nm
perimeter)

330
1.54
918

241
1.03
1,425

p<0.01

331
1.35
1,137

p=0.07

%MAM with gap-width ≤10nm
%MAM with gap-width ≤25nm
%MAM with gap-width ≤50nm
%MAM with gap-width ≤100nm

22%
47%
68%
100%

17%
43%
73%
100%
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p<0.01

p=0.09
p= ns
p= ns

15%
40%
71%
100%

p= ns

p=0.02
p<0.05
p= ns

CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS
Due to the extremely heterogenous landscape of cancer cells even within one
histiotype and the multifactorial nature of resistance, understanding and simplifying
cancer resistance mechanisms into a unified paradigm has presented a fundamental
challenge. The diversity of cancer drug targets, stress pathways and potential
adaptations employed by cancer cells precludes defining a single process by which all
treatments impact cell state. Historically multidrug resistance has been more generally
classified into three resistance mechanisms that involve pathway reactivation, pathway
bypass and pathway indifference.170 Considering that resistance effectors are not
randomly distributed, that cancer therapeutic stressors engage both ER stress171–173 and
mitochondria-regulated programmed cell death and that many alternative stress
pathways also utilize mitochondrial apoptosis as a terminal effector [including mitotic
catastrophe]174, extended mitotic arrest175, and necroptosis we hypothesized a unique
“post-drug target” convergence based-framework of resistance that arises from
dysregulated ERMCs. It is well established that mitochondrial activities are intimately
linked to ER functions, and that these two organelles interact dynamically via
proteinacious tethers at specialized contact sites called mitochondria-associated
membranes (MAMs) that are essential for the transfer of calcium (Ca2+) and lipid signals
and regulation of apoptotic sensitivity. The relevance of ERMCs to pathogenesis has
been an area of investigation for a long time with alterations in ER-mitochondrial
tethering increasingly linked to pathological responses, such as cardiac

and ototoxic

injury177, as well as disease states of deregulated cell survival or metabolism. In
Parkinson’s, Alzheimer’s disease and ALS enhanced ER-mitochondria coupling is
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implicated in increased neuronal death6,7,49,178,179. Obesity has also been linked to
increased tethering and deregulated metabolism leading to type 2 diabetes, further
supporting this as a dynamic phenotype that is deregulated in disease15,17. The first
observations that ER-mitochondria tethering might be altered in cancer were made by
Howatson and Ham upon noticing reduced number of mitochondria and ERMCs in
mouse liver cancer180–183. Very recent studies have described the functional significance
of aberrant Ca2+ signaling at ERMCs in an aggressive neoplasm112,184. However, ERMC
remodeling has not been elucidated in the setting of cancer progression and therapy
resistance, where we postulated a progressive loss of tethering across the treatment
continuum as an adaptive survival response of cancer cells under intense and prolonged
therapeutic stress.
In the present study we define a novel mechanism for therapy resistance caused
by reductions in ERMC tethering, provide functional validations for this relationship and
strengthening evidence for MAM structures as emerging regulators of cancer growth.
We show that REL neuroblastomas have markedly decreased mitochondrial apoptotic
response, reduced ERMC connectivity, reduced MAM content, increased number of
orphan mitochondria (devoid of MAMs) and differential expression of various tethering
proteins confirming the role of ERMCs in determining mitochondrial apoptotic and
chemotherapy responses.
We used a BH3 profiling mitochondrial assay originally developed by Letai for
predicting chemosensitivity35,45,184 to discover that mitochondria from resistant cancers
have markedly reduced apoptotic responses to the bona fide death signals, tBid and
Bim, providing the first evidence that attenuated mitochondrial signaling is acquired
under the selective pressure of multimodality therapy leading to multidrug resistance.
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Using isolated crude mitochondria containing MAMs, the assay measures only the
commitment step in mitochondrial death signaling so is agnostic to upstream signals.
This approach applied to our matched tumors enabled the discovery that these
mitochondria have reduced physical coupling with ER, a phenotype that is more difficult
to identify in the context of heterogeneous tumor comparisons.
As shown by Chipuk et al., crude mitochondria of mouse embryonic fibroblasts
devoid of MAMs had a blunted mitochondria apoptotic response to direct activator
stimulation, but mitochondrial sensitivity to direct activator stimulation was restored upon
addition of MAMs, suggesting that MAMs contain essential signals for apoptosis
sensitivity.185 Consistent with these findings, we could phenocopy therapy resistance to
Bim and apoptotic stimuli at the mitochondrial level in DX neuroblastoma in which MAMs
were separated from the mitochondria physically, chemically and genetically by silencing
of tethering proteins. We could recapitulate this resistance to various chemotherapies at
the cellular level in tether-reduced DX cells. Furthermore, the qualitative observation that
REL neuroblastoma have qualitatively reduced MAM content, confirms the functional
significance of MAMs in cancer therapy resistance. Taken together, these finding
indicate that MAMs serve as physiologic regulators of apoptosis and that reductions of
ER-mitochondria tethering could comprise an adaptive survival response of cancer cells
under intense and prolonged therapeutic stress.
Since Ca2+ transport at ERMCs plays a crucial role in cell death and survival and
attenuated ER-derived Ca2+ signaling is a well-known function and mechanism of
resistance to apoptosis, we pursued the study of Ca2+ signaling at MAMs as a primary
contributor to broad therapy resistance. Recently Pinton et al. found that malignant
pleural mesothelioma (MPM) cell lines and short-term cultures obtained from MPM-
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affected patients exhibited a critical dysregulation in ER-derived Ca2+ signaling at MAMS
associated with resistance to apoptotic stimuli48,52,58,119,120,172,186,187.
While our studies revealed a significant four-fold reduction of ER-derived Ca2+
signaling in BE2C resistant cells (with the most detethered phenotype across all bins),
we did not observe any calcium transfer changes in the CHLA15 and CHLA20 pair (with
23% decreased tether in <10 nm distance bin) revealing that the dysregulation of ERderived Ca2+ signaling at MAMS was not a shared resistance mechanism between the
two REL neuroblastomas. The recoupling of these two organelles via synthetic tethers in
BE2C restored calcium signaling, suggesting that the degree of detethering and the
physical properties of the ER-mitochondria interface affect Ca2+ transfer at these
microdomains. Indeed, Csordas et al. elegantly describe how the efficiency of Ca2+
transfer is dependent upon the space (gap-width) between the two organelles and the
special arrangements of Ca2+ transport channels, suggesting that different subsets of
contact sites with different spatial requirements exist to support distinct functions of the
ER-mitochondrial interface in calcium coupling, lipid transfer and protein trafficking51.
We also considered whether other factors independent of tethering could affect
Ca2+ entry into mitochondria downstream of tethering, in particular mitochondrial Ca2+
uptake by MCU. Reduced expression of MCU was found to attenuate mitochondrial Ca2+
levels and the latter to suppress cell death in cervix, central nervous system and lymph
tissue-derived cell lines, including those derived from the cervix, central nervous system
and lymph tissues75,188,189. Likewise, both human colon and prostate cancer cells have
reduced MCU levels190, as do patient-derived of malignant pleural mesothelioma cells, in
which MCU overexpression restored mitochondrial Ca2+, apoptotic response and
reduced cell growth184. Hence, we measured MCU expression in our DX/REL but found
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no differences. To test our hypothesis if impaired mitochondrial Ca2+ entry would affect
the apoptotic sensitivity, we pair genetically silenced the MCU and chemically inhibited it
by ruthenium-360, a potent inhibitor of the MCU, in our two DX/REL pairs, but found no
differences in attenuated mitochondrial responses or increased cytotoxicity to ABT-737
due to inhibition of MCU. Taken together, these findings indicate that aberrant calcium
signaling at MAM’s is not a shared-resistance mechanism at MAMs and that other MAM
factors play a role in modulating an apoptotic sensitivity.
When trying to explain patient-specific differences in Ca2+ transfer, we probed the
differential expression of various MAM proteins both in whole cell and crude
mitochondria lysates. Of note, in CHLA20 crude mitochondrial preps we found a
significant 3-fold increase in DRP-1, a mitochondrial outer membrane protein
responsible for mitochondrial fission through interaction with ER at ERMCs. Mouse
Drp1 deficient muscle mitochondria are bigger and have increased mitochondrial
Ca2+uptake and myofiber death191. In fact, DRP1 is a target of multiple post-translational
modifications, including sumoylation and phosphorylation. MAPL SUMOylates DRP1 at
the ER/mitochondria interface during apoptosis and both MAPL and mitochondrial
SUMOylation are required for an efficient cell death downstream of BAX/BAX
oligomerization and activation. Additionally, p-DRP1 (Ser616) was highly expressed in
nasopharyngeal carcinoma tissues, whereas p-DRP1 (Ser637) expression was
suppressed

leading

to

fragmented

mitochondria

and

cisplatin

resistance165.

Morphologically, CHLA20 also result to be smaller and rounder than the CHLA15.
Hyperfragmented mitochondria fail to support BAX-dependent membrane association
and permeabilization due to an inability to stabilize BAXa9membrane interactions192.
However, in previous studies we did not observe any difference in BAX/BAK
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oligomerization, hence it is highly probably that given the increased DRP-1 levels, DRP1

dependent

mitochondrial

dynamics

and

mitochondrial

cristae

remodeling160,164,165,191,193,194 are contributing to the therapy resistance in this pair.
We demonstrate that in the BE2C patient with the most de-tethered phenotype
and an acquired p53 mutation, altered Ca2+ signaling at these contact sites plays a
principal role in the resistance phenotype. A critical non-transcriptional role of
cytoplasmic p53 at the ER-mitochondria contact sites has been described by Giogi et al.
They show that wild type cytoplasmic p53 directly binds to the sarco/ER Ca2+-ATPase
(SERCA) pump at the ER, consequently changing its oxidative state and thus leading to
an increased Ca2+ load, more enhanced Ca2+ transfer to mitochondria and apoptosis
induction. On the other hand, mutant p53 or pharmacological inactivation of wild type
p53 inhibits SERCA pump activity at the ER. Indeed, BE2C harbors a p53 missense
mutation and shows a more than 3-fold increased expression of SERCA in crude
mitochondrial protein preparations compared to BE1. Upregulation of SERCA would
mean increased pumping of Ca2+ back into the ER, ensuing in Ca2+ depletion at ERMCs.
Pharmacologically or genetically inhibiting SERCA in BE2C would in part restore calcium
signaling. Equally importantly, restoring the activity of cytoplasmic p53 in BE2C followed
by functional studies to measure improved tethering, mitochondrial competency and
Ca2+ transfer comprise the next steps in delineating the underlying Ca2+-dependent
mechanism for this patient.
Since Ca2+ and lipid transfer at ERMCs are not mutually exclusive, ongoing lab
studies are investigating the role of lipid signaling at ERMCs on therapy resistance.
Alterations in the lipid composition of MAMs and mitochondrial membranes can have
implications in both the stability of tethering proteins on both sides of ERMCs and the
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release of cytochrome c from the IMM. Profiling the lipid composition of crude
mitochondria as well as purified MAMs and mitochondrial components and quantifying
lipid transfer between ERMCs in our isogenic cell line pairs will elucidate their
contribution on apoptotic lipid signaling.
Ceramide has been described as a key regulator of programmed cell death and
as tumor-suppressor lipid. Defects in ceramide generation and sphingolipid metabolism
at ERMCs have been implicated in cancer cell survival and cancer therapy
resistance132,195. Chipuk

et

al

showed

how

sphingolipid

metabolism

regulates

mitochondrial sensitivity to apoptosis, BAK and BAX activation and clonogenic survival.
Additionally, they demonstrate that cytoplasmic p53 interacts with Bcl-xL on
mitochondria preventing it from disassembling ceramide and Bax channels185,196.
Sano et al. describe how GM1-ganglioside accumulates in the glycosphingolipidenriched microdomain (GEM) fractions of MAMs of neuronal cells, where it interacts with
the phosphorylated form of IP3 receptor-1, increasing the Ca2+ flux at ERMCs and
leading to Ca2+ overload and neuronal cell death197.
Our studies carry certain limitation worth considering and exploring in the future.
Because we utilize neuroblastoma cell line models to study therapy resistance, we miss
accounting for intra-tumoral heterogeneity and the impact it has on driving clonal
selection under therapeutic pressure. Most of our assays are bulk assays of cell
populations, which capture cell population averages, but not cell-to-cell heterogeneity.
Though neuroblastoma tumours harbor few somatic mutations, they exhibit significant
intratumor heterogeneity. In fact, the presence of

neuroblastoma subpopulations of

stem cell-like progenitors or tumor-initiating cells expressing stem cell factor (SCF) and
its receptor c-kit , has been well established since three decades ago .
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Lately, two phenotypically divergent lineage states with distinct gene expression
profiles and resembling cells from different lineage development stages have been
described. They are derived from the I-type (intermediate) progenitor cells that become
either the N-type (neuroblastic) sympathoadrenal neuroblasts with short neuritic
processes expressing an adrenergic gene signature or the,S-type (substrate-adherent)
cells had glial or Schwannian-like characteristics with a mesenchymal gene signature.
and I-type (intermediate) cells express features of both N- and S-type cells. The two
capable of interconversion26.
More recently, van Groningen and colleagues molecularly and phenotypically
characterized several isogenic neuroblatoma pairs. Despite of the fact that they
possessed similar genomic alterations, some isogenic cells expressed CD133, a marker
for tumor stem cell, and some did not. CD133+ cell lines presented a motile phenotype
and expressed a mesenchymal-associated gene signature, whereas CD133− cell lines
exhibited a nonmigratory phenotype and expressed an adrenergic differentiation–
associated

gene

signature199.

Molecularly

targeting

mesenchymal

CD133+ neuroblastoma cells, may offer an effective strategy to prevent relapse.
Moreover, they describe how super-enhancer-associated transcription factor
networks underlie this lineage identity. The differences in heterogeneity become
potentially important as we parse out dynamic drivers that determine adrenergic and
mesenchymal lineage states of neuroblastoma and their effect on therapy resistance.
Probing into the marks of epigenetic states and exploring the altered epigenetic
landscape remains an area of investigation for the lab.
Outstanding questions remain. Identifying factors and mechanisms that regulate
the formation and dissolution of ERMCs comprises another key area for future research,

-89-

not only for our lab, but for the field in general.

Identifying the full complement of

tethering proteins and especially understanding the mechanisms that regulate
interactions between tethers under both normal physiological and pathological conditions
would provide more insights and opportunities for therapeutic intervention in MDR
patients and other pathophysiologies involving dysregulated ERMCs. Do all multimodal
therapy insults target the tethers and, if so, by what mechanism do they induce ERmitochondria social distancing?
Particular focus should be placed on proteins that regulate the extent of the ER–
mitochondria tethering as well as the function of the active proteins in the contacts such
as that of cytoplasmic p53 that changes the redox state of Ca2+ handling proteins,
thence regulating ERMC juxtaposition112.
Recently,

however

the

repertoire

of

ERMC

regulators

is

expanding.

Transglutaminase type 2 (TG2), a multifunctional enzyme that plays a key role in
mitochondria homeostasis under stressful cellular conditions was identified to interact
with GRP75 in MAM, preventing GRP75 interaction with IP3R. The absence of the TG2GRP75 interaction led to an increased IP3R-3 and GRP75 interaction, decreased ERMC
number and impaired ER-mitochondrial Ca2+ flux78.
Glycogen synthase kinase-3β (GSK-3β) has been described to disrupt the
VAPB–PTPIP51 tethering complex in amyotrophic lateral sclerosis and frontotemporal
dementia (ALS/FTD)92,200. TDP-43 activates GSK-3β by inhibitory phosphorylation of
serine-9, consequently inhibiting VAPB-PTPIP51 interaction and suggesting that suggest
that ERMC may be perturbed by TDP-43 .
In conclusion, my thesis work presents a novel mechanism for the profound
resistance to multi-modal therapy seen in numerous cancers in the clinic, the principal
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cause of cancer treatment failure and facilitates the development of clinically useful tools
to measure ER-mitochondria interactions and provides a novel framework for testing
interventions to prevent emergent therapy resistance or restore mitochondrial
competence to resistant cancers. I have developed fundamental knowledge of the
determinants of therapy response in neuroblastoma and provide a platform for studies
that may contribute significantly to improving outcomes across diverse cancers.
With the advances in diagnostic techniques the development of proximity ligation
assays to quantify ER-mitochondrial interactions in fixed cells and will prove highly
beneficial in making informed decisions about effective therapies in clinic. Probing into
neuroblastoma tumor biology to determine the spatial-temporal progression of the ERmitochondria de-tethering as it pertains to therapy sensitivity will require obtaining
samples at diagnosis and after each treatment cycle. More recently Scorrano et al.
devised a one-step imaging technique in live human cells called split-GFP-based contact
site sensor (SPLICS) that specifically identifies narrow and wide ERMCs between 10
and 50 nm and which can be easily adapted to measure ERMCs over a range of
distances91,149. Extending such diagnostics to other tumor types, both pediatric and adult,
will provide deeper insights on the contribution of ERMCs to cancer progression and
resistance across a wide repertoire of malignancies.
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